US8088361B2	NNP	O
-	:	O
Treatment	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
in	IN	O
mammals	NNS	O
with	IN	O
Clostridia	NNP	O
neurotoxins	NNS	O
-	:	O
Google	NNP	O
Patents	NNP	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS	NNP	O
REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/535,504	CD	O
,	,	O
filed	VBN	O
on	IN	O
May	NNP	O
18	CD	O
,	,	O
2005	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,879,340	CD	O
,	,	O
filed	VBD	O
as	IN	O
International	NNP	O
Application	NNP	O
No	NNP	O
.	.	O
PCT/US03/37286	NN	O
on	IN	O
Nov.	NNP	O
20	CD	O
,	,	O
2003	CD	O
,	,	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Application	NNP	O
No	NNP	O
.	.	O
60/427,749	CD	O
,	,	O
filed	VBD	O
Nov.	NNP	O
21	CD	O
,	,	O
2002	CD	O
.	.	O
FIELD	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
A	NNP	O
method	NN	O
is	VBZ	O
disclosed	VBN	O
for	IN	O
blocking	VBG	O
or	CC	O
reducing	VBG	O
physiological	JJ	O
reaction	NN	O
in	IN	O
a	DT	O
mammal	NN	O
to	TO	O
the	DT	O
interaction	NN	O
of	IN	O
IgE	NNP	O
antibodies	NNS	O
present	VBP	O
in	IN	O
said	VBD	O
mammal	JJ	O
upon	IN	O
contact	NN	O
with	IN	O
the	DT	O
corresponding	JJ	O
antigen	NN	O
,	,	O
by	IN	O
the	DT	O
administration	NN	O
to	TO	O
said	VBD	O
mammal	NN	O
of	IN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
neurotoxin	NN	O
(	(	O
CnT	NNP	O
)	)	O
derived	VBD	O
from	IN	O
Clostridia	NNP	O
sp	NN	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Throughout	NNP	O
this	DT	O
application	NN	O
various	JJ	O
publications	NNS	O
are	VBP	O
referred	VBN	O
to	TO	O
within	IN	O
parentheses	NNS	O
or	CC	O
by	IN	O
footnote	NN	O
.	.	O
The	DT	O
contents	NNS	O
of	IN	O
these	DT	O
publications	NNS	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
INTRODUCTION	NNP	O
The	DT	O
physiological	JJ	O
reaction	NN	O
in	IN	O
a	DT	O
mammal	NN	O
to	TO	O
the	DT	O
interaction	NN	O
of	IN	O
IgE	NNP	O
antibodies	NNS	O
present	VBP	O
in	IN	O
said	VBD	O
mammal	JJ	O
upon	IN	O
contact	NN	O
with	IN	O
the	DT	O
corresponding	JJ	O
antigen	NN	O
is	VBZ	O
generally	RB	O
referred	VBN	O
to	TO	O
as	IN	O
allergy	NN	O
.	.	O
It	PRP	O
is	VBZ	O
believed	VBN	O
that	IN	O
the	DT	O
allergic	JJ	O
response	NN	O
evolved	VBD	O
to	TO	O
combat	VB	O
infections	NNS	O
with	IN	O
parasites	NNS	O
.	.	O
As	IN	O
parasitic	JJ	O
infections	NNS	O
are	VBP	O
rare	JJ	O
in	IN	O
industrialized	JJ	O
countries	NNS	O
this	DT	O
mechanism	NN	O
becomes	VBZ	O
pathologic	JJ	O
in	IN	O
certain	JJ	O
susceptible	JJ	O
(	(	O
atopic	NN	O
)	)	O
individuals	NNS	O
.	.	O
Characteristic	NNP	O
of	IN	O
allergies	NNS	O
is	VBZ	O
that	IN	O
the	DT	O
antigen	NN	O
,	,	O
also	RB	O
called	VBD	O
the	DT	O
allergen	NN	O
,	,	O
is	VBZ	O
normally	RB	O
innocuous	JJ	O
,	,	O
and	CC	O
the	DT	O
body	NN	O
's	POS	O
reaction	NN	O
is	VBZ	O
inappropriate	JJ	O
.	.	O
Allergic	JJ	O
reactions	NNS	O
can	MD	O
involve	VB	O
all	DT	O
body	NN	O
tissues	NNS	O
but	CC	O
are	VBP	O
most	JJS	O
prominent	JJ	O
in	IN	O
the	DT	O
boundaries	NNS	O
with	IN	O
the	DT	O
external	JJ	O
environment	NN	O
:	:	O
the	DT	O
airway	NN	O
,	,	O
eye	NN	O
,	,	O
gastrointestinal	JJ	O
tract	NN	O
and	CC	O
skin	NN	O
.	.	O
The	DT	O
conditions	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
allergic	JJ	O
rhinitis	NN	O
in	IN	O
the	DT	O
nose	NN	O
(	(	O
hay	JJ	O
fever	NN	O
)	)	O
,	,	O
allergic	JJ	O
asthma	NN	O
in	IN	O
the	DT	O
lungs	NNS	O
,	,	O
food	NN	O
allergies	NNS	O
in	IN	O
the	DT	O
GI	NNP	O
tract	NN	O
and	CC	O
allergic	JJ	O
hypersensitivity	NN	O
(	(	O
hives	NNS	O
)	)	O
or	CC	O
dermatitis	NN	O
in	IN	O
the	DT	O
skin	NN	O
.	.	O
Anaphylaxis	NNP	O
refers	NNS	O
to	TO	O
the	DT	O
systemic	JJ	O
reaction	NN	O
that	WDT	O
occurs	VBZ	O
when	WRB	O
an	DT	O
allergen	NN	O
is	VBZ	O
introduced	VBN	O
directly	RB	O
into	IN	O
the	DT	O
circulation	NN	O
,	,	O
such	JJ	O
as	IN	O
occurs	NNS	O
with	IN	O
injection	NN	O
of	IN	O
drugs	NNS	O
and	CC	O
insect	JJ	O
stings	NNS	O
.	.	O
A	DT	O
massive	JJ	O
early	JJ	O
phase	NN	O
reaction	NN	O
occurs	VBZ	O
throughout	IN	O
the	DT	O
body	NN	O
.	.	O
Symptoms	NNP	O
include	VBP	O
diffuse	VB	O
airway	JJ	O
swelling	VBG	O
and	CC	O
hypotension	NN	O
which	WDT	O
can	MD	O
be	VB	O
life	NN	O
threatening	VBG	O
.	.	O
Each	DT	O
year	NN	O
more	JJR	O
than	IN	O
50	CD	O
million	CD	O
Americans	NNPS	O
suffer	VBP	O
from	IN	O
allergic	JJ	O
diseases	NNS	O
,	,	O
costing	VBG	O
the	DT	O
health	NN	O
care	NN	O
system	NN	O
$	$	O
18	CD	O
billion	CD	O
annually	RB	O
(	(	O
American	JJ	O
Academy	NNP	O
of	IN	O
Allergy	NNP	O
,	,	O
Asthma	NNP	O
and	CC	O
Immunology	NNP	O
(	(	O
AAAAI	NNP	O
)	)	O
.	.	O
The	DT	O
Allergy	NNP	O
Report	NNP	O
:	:	O
Science	NN	B
Based	VBD	I
Findings	NNS	I
on	IN	I
the	DT	I
Diagnosis	NNP	I
&	CC	I
Treatment	NNP	I
of	IN	I
Allergic	NNP	I
Disorders	NNP	I
,	,	I
1996-2001	JJ	I
)	)	O
.	.	O
Alarmingly	RB	O
,	,	O
the	DT	O
prevalence	NN	O
and	CC	O
severity	NN	O
of	IN	O
allergic	NN	O
disorders	NNS	O
has	VBZ	O
rapidly	RB	O
increased	VBN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
over	IN	O
the	DT	O
past	JJ	O
twenty	NN	O
years	NNS	O
,	,	O
so	IN	O
there	EX	O
is	VBZ	O
a	DT	O
need	NN	O
for	IN	O
new	JJ	O
therapies	NNS	O
for	IN	O
these	DT	O
conditions	NNS	O
.	.	O
In	IN	O
1998	CD	O
,	,	O
an	DT	O
estimated	VBN	O
15	CD	O
million	CD	O
Americans	NNPS	O
,	,	O
or	CC	O
6.4	CD	O
percent	NN	O
of	IN	O
the	DT	O
population	NN	O
,	,	O
had	VBD	O
asthma	VBN	O
,	,	O
with	IN	O
5	CD	O
million	CD	O
being	VBG	O
children	NNS	O
.	.	O
Children	NNP	O
account	NN	O
for	IN	O
4.8	CD	O
million	CD	O
of	IN	O
Americans	NNPS	O
with	IN	O
asthma	NN	O
.	.	O
Each	DT	O
year	NN	O
,	,	O
1.8	CD	O
million	CD	O
emergency	NN	O
room	NN	O
visits	NNS	O
are	VBP	O
for	IN	O
asthma	NN	O
,	,	O
nearly	RB	O
500,000	CD	O
Americans	NNPS	O
are	VBP	O
hospitalized	VBN	O
and	CC	O
more	JJR	O
than	IN	O
5,000	CD	O
die	NN	O
from	IN	O
the	DT	O
disease	NN	O
.	.	O
Although	IN	O
asthma	JJ	O
deaths	NNS	O
are	VBP	O
infrequent	JJ	O
,	,	O
they	PRP	O
have	VBP	O
increased	VBN	O
significantly	RB	O
during	IN	O
the	DT	O
last	JJ	O
two	CD	O
decades	NNS	O
.	.	O
From	IN	O
1975-1979	CD	O
,	,	O
the	DT	O
death	NN	O
rate	NN	O
was	VBD	O
8.2	CD	O
per	IN	O
100,000	CD	O
people	NNS	O
.	.	O
That	DT	O
rate	NN	O
jumped	VBD	O
in	IN	O
1993-1995	JJ	O
to	TO	O
17.9	CD	O
per	IN	O
100,000	CD	O
.	.	O
Asthma	NNP	O
cost	VBD	O
the	DT	O
U.S.	NNP	O
economy	NN	O
an	DT	O
estimated	JJ	O
$	$	O
10.7	CD	O
billion	CD	O
in	IN	O
1994	CD	O
,	,	O
including	VBG	O
a	DT	O
direct	JJ	O
health	NN	O
care	NN	O
cost	NN	O
of	IN	O
$	$	O
6.1	CD	O
billion	CD	O
and	CC	O
indirect	JJ	O
costs	NNS	O
,	,	O
such	JJ	O
as	IN	O
lost	VBN	O
workdays	NNS	O
,	,	O
of	IN	O
$	$	O
4.6	CD	O
billion	CD	O
.	.	O
Approximately	RB	O
16.7	CD	O
million	CD	O
office	NN	O
visits	NNS	O
to	TO	O
health	NN	O
care	NN	O
providers	NNS	O
each	DT	O
year	NN	O
are	VBP	O
attributed	VBN	O
to	TO	O
allergic	VB	O
rhinitis	NN	O
alone	RB	O
(	(	O
CDC	NNP	B
.	.	I
Fast	NNP	I
Stats	NNP	I
A-Z	NNP	I
,	,	I
Vital	NNP	I
and	CC	I
Health	NNP	I
Statistics	NNPS	I
,	,	I
Series	NNP	I
10	CD	I
,	,	I
no	DT	I
.	.	I
13	CD	I
.	.	I
1999	CD	I
A	NNP	O
related	JJ	O
condition	NN	O
,	,	O
chronic	JJ	O
sinusitis	NN	O
,	,	O
is	VBZ	O
the	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
chronic	JJ	O
disease	NN	O
,	,	O
affecting	VBG	O
12.6	CD	O
percent	NN	O
of	IN	O
people	NNS	O
(	(	O
approximately	RB	O
38	CD	O
million	CD	O
)	)	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
in	IN	O
1996	CD	O
.	.	O
Another	DT	O
related	JJ	O
condition	NN	O
,	,	O
serous	JJ	O
otitis	NN	O
media	NNS	O
,	,	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
condition	NN	O
in	IN	O
children	NNS	O
requiring	VBG	O
an	DT	O
office	NN	O
visit	NN	O
to	TO	O
a	DT	O
health	NN	O
care	NN	O
provider	NN	O
.	.	O
Atopic	NNP	O
dermatitis	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
common	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
particularly	RB	O
in	IN	O
infants	NNS	O
and	CC	O
children	NNS	O
.	.	O
The	DT	O
estimated	VBN	O
prevalence	NN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
is	VBZ	O
9	CD	O
percent	NN	O
Rudikoff	NNP	B
D	NNP	I
and	CC	I
Lebwohl	NNP	I
M.	NNP	I
“	NNP	I
Atopic	NNP	I
dermatitis.	NN	I
”	NNP	I
Lancet	NNP	I
351	CD	I
(	(	I
9117	CD	I
)	)	I
:	:	I
1715-21	JJ	I
.	.	I
1998	CD	I
Experts	NNS	O
estimate	VBP	O
that	IN	O
food	NN	O
allergy	NN	O
occurs	VBZ	O
in	IN	O
8	CD	O
percent	NN	O
of	IN	O
children	NNS	O
6	CD	O
years	NNS	O
of	IN	O
age	NN	O
or	CC	O
under	IN	O
,	,	O
and	CC	O
in	IN	O
1	CD	O
to	TO	O
2	CD	O
percent	NN	O
of	IN	O
adults	NNS	O
Sampson	NNP	B
H	NNP	I
A	NNP	I
.	.	I
In	IN	I
Allergy	NNP	I
,	,	I
Principles	NNP	I
and	CC	I
Practice	NNP	I
,	,	I
5th	CD	I
Ed.	NNP	I
,	,	I
E.	NNP	I
Middleton	NNP	I
et	FW	I
al	NN	I
,	,	I
ed	NN	I
.	.	I
Mosby	NNP	I
,	,	I
St.	NNP	I
Louis	NNP	I
,	,	I
p.	NN	I
1162	CD	I
.	.	I
1998	CD	I
Pathophysiology	NNP	O
of	IN	O
Allergy	NNP	O
Allergy	NNP	O
is	VBZ	O
an	DT	O
ailment	NN	O
that	WDT	O
affects	VBZ	O
millions	NNS	O
of	IN	O
individuals	NNS	O
worldwide	VBP	O
.	.	O
Attempts	NNS	O
to	TO	O
desensitize	VB	O
an	DT	O
individual	NN	O
against	IN	O
a	DT	O
material	NN	O
that	WDT	O
causes	VBZ	O
an	DT	O
allergic	JJ	O
response	NN	O
(	(	O
hereafter	RB	O
designated	VBN	O
as	IN	O
an	DT	O
“	NN	O
allergen	NN	O
”	NN	O
)	)	O
by	IN	O
injection	NN	O
of	IN	O
measured	JJ	O
dosages	NNS	O
of	IN	O
the	DT	O
allergen	NN	O
heretofore	NN	O
has	VBZ	O
failed	VBN	O
to	TO	O
achieve	VB	O
complete	JJ	O
relief	NN	O
of	IN	O
allergy	NN	O
symptoms	NNS	O
reproducibly	RB	O
in	IN	O
all	DT	O
allergic	JJ	O
individuals	NNS	O
.	.	O
An	DT	O
allergic	JJ	O
response	NN	O
is	VBZ	O
a	DT	O
term	NN	O
of	IN	O
art	NN	O
and	CC	O
has	VBZ	O
a	DT	O
well-defined	JJ	O
meaning	NN	O
.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
an	DT	O
allergic	NN	O
or	CC	O
reagenic	JJ	O
response	NN	O
includes	VBZ	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
features	NNS	O
of	IN	O
1	CD	O
.	.	O
)	)	O
production	NN	O
of	IN	O
an	DT	O
abnormally	RB	O
high	JJ	O
level	NN	O
of	IN	O
IgE	NNP	O
in	IN	O
an	DT	O
individual	NN	O
's	POS	O
serum	NN	O
,	,	O
2	CD	O
.	.	O
)	)	O
immunologic	JJ	O
interaction	NN	O
between	IN	O
an	DT	O
allergen	NN	O
,	,	O
an	DT	O
individual	NN	O
's	POS	O
IgE	NNP	O
and	CC	O
leukocytes	VBZ	O
resulting	VBG	O
in	IN	O
release	NN	O
of	IN	O
histamines	NNS	O
,	,	O
3	CD	O
.	.	O
)	)	O
production	NN	O
of	IN	O
hives	NNS	O
,	,	O
rashes	NNS	O
,	,	O
wheal	NN	O
and	CC	O
flare	NN	O
and	CC	O
similar	JJ	O
dermatological	JJ	O
manifestation	NN	O
of	IN	O
hypersensitivity	NN	O
,	,	O
and	CC	O
4	CD	O
.	.	O
)	)	O
anaphylaxis	NN	O
.	.	O
An	DT	O
allergic	JJ	O
response	NN	O
is	VBZ	O
a	DT	O
state	NN	O
of	IN	O
hypersensitivity	NN	O
in	IN	O
which	WDT	O
an	DT	O
exaggerated	JJ	O
immune	NN	O
response	NN	O
is	VBZ	O
induced	VBN	O
by	IN	O
the	DT	O
exposure	NN	O
to	TO	O
a	DT	O
particular	JJ	O
antigen	NN	O
or	CC	O
allergen	NN	O
.	.	O
Hypersensitivity	NNP	O
reactions	NNS	O
can	MD	O
be	VB	O
classified	VBN	O
as	IN	O
immediate	JJ	O
or	CC	O
delayed	VBN	O
.	.	O
Immediate	NNP	O
or	CC	O
type	NN	O
I	PRP	O
hypersensitivity	NN	O
(	(	O
or	CC	O
anaphylactic	JJ	O
response	NN	O
)	)	O
is	VBZ	O
an	DT	O
allergic	JJ	O
reaction	NN	O
which	WDT	O
develops	VBZ	O
very	RB	O
quickly	RB	O
,	,	O
i.e.	FW	O
,	,	O
within	IN	O
seconds	NNS	O
or	CC	O
minutes	NNS	O
of	IN	O
exposure	NN	O
of	IN	O
the	DT	O
patient	NN	O
to	TO	O
the	DT	O
causative	JJ	O
allergen	NN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
mediated	VBN	O
by	IN	O
IgE	NNP	O
antibodies	NNS	O
produced	VBN	O
by	IN	O
B	NNP	O
lymphocytes	NNS	O
.	.	O
In	IN	O
non-allergic	JJ	O
patients	NNS	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
IgE	NNP	O
antibody	NN	O
of	IN	O
clinical	JJ	O
relevance	NN	O
.	.	O
However	RB	O
,	,	O
in	IN	O
a	DT	O
person	NN	O
suffering	VBG	O
with	IN	O
allergic	JJ	O
diseases	NNS	O
,	,	O
IgE	NNP	O
antibody	NN	O
mediates	VBZ	O
immediate	JJ	O
hypersensitivity	NN	O
by	IN	O
sensitizing	VBG	O
mast	NN	O
cells	NNS	O
which	WDT	O
are	VBP	O
abundant	JJ	O
in	IN	O
the	DT	O
skin	NN	O
,	,	O
membranes	NNS	O
of	IN	O
the	DT	O
eye	NN	O
,	,	O
nose	JJ	O
and	CC	O
mouth	NN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
respiratory	NN	O
tract	NN	O
and	CC	O
intestines	NNS	O
.	.	O
IgE	NNP	O
secreted	VBD	O
from	IN	O
activated	VBN	O
B	NNP	O
cells	NNS	O
can	MD	O
attach	VB	O
to	TO	O
Fc	NNP	O
receptors	NNS	O
located	VBD	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
mast	NN	O
cells	NNS	O
and	CC	O
basophil	NN	O
granulocytes	NNS	O
,	,	O
which	WDT	O
contain	VBP	O
numerous	JJ	O
cytoplasmic	JJ	O
granules	NNS	O
packed	VBN	O
with	IN	O
chemical	JJ	O
mediators	NNS	O
e.g	VBP	O
.	.	O
histamine	NN	O
(	(	O
J.	NNP	B
Klein	NNP	I
,	,	I
“	NNP	I
Immunology	NNP	I
”	NNP	I
,	,	I
Blackwell	NNP	I
Sci	NNP	I
.	.	I
Pub.	NNP	I
,	,	I
London	NNP	I
,	,	I
1990	CD	I
;	:	O
E.	NNP	B
Benjamini	NNP	I
&	CC	I
S.	NNP	I
Leskowitz	NNP	I
,	,	I
“	NNP	I
Immunology	NNP	I
”	NNP	I
,	,	I
Wiley-Liss	NNP	I
,	,	I
N.Y.	NNP	I
1991	CD	I
)	)	O
.	.	O
This	DT	O
receptor	NN	O
binds	VBZ	O
circulating	VBG	O
IgE	NNP	O
with	IN	O
very	RB	O
high	JJ	O
affinity	NN	O
and	CC	O
retains	VBZ	O
it	PRP	O
at	IN	O
the	DT	O
mast	NN	O
cell	NN	O
surface	NN	O
for	IN	O
extended	JJ	O
periods	NNS	O
of	IN	O
time	NN	O
.	.	O
Activation	NN	O
is	VBZ	O
accomplished	VBN	O
through	IN	O
the	DT	O
binding	NN	O
of	IN	O
an	DT	O
allergen	NN	O
simultaneously	RB	O
to	TO	O
more	JJR	O
than	IN	O
one	CD	O
polyvalent	NN	O
molecule	NN	O
of	IN	O
Fc	NNP	O
receptor-bound	NN	O
IgE	NNP	O
.	.	O
This	DT	O
“	NNP	O
cross	NN	O
linking	VBG	O
”	NN	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
surface-bound	JJ	O
IgE	NNP	O
molecules	NNS	O
brings	VBZ	O
Fc	NNP	O
receptor	NN	O
proteins	VBZ	O
into	IN	O
close	JJ	O
association	NN	O
with	IN	O
one	CD	O
another	DT	O
in	IN	O
the	DT	O
plane	NN	O
of	IN	O
the	DT	O
mast	NN	O
cell	NN	O
plasma	NN	O
membrane	NN	O
.	.	O
When	WRB	O
the	DT	O
bound	NN	O
IgE	NNP	O
is	VBZ	O
contacted	VBN	O
by	IN	O
the	DT	O
appropriate	JJ	O
allergen	NN	O
,	,	O
the	DT	O
mast	NN	O
cell	NN	O
becomes	RB	O
activated	VBD	O
.	.	O
Kinases	NNS	O
associated	VBN	O
with	IN	O
these	DT	O
receptors	NNS	O
become	VBP	O
activated	VBN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
this	DT	O
proximity	NN	O
.	.	O
They	PRP	O
initiate	VBP	O
the	DT	O
second	JJ	O
messenger	NN	O
cascade	NN	O
,	,	O
which	WDT	O
results	NNS	O
in	IN	O
the	DT	O
fusion	NN	O
of	IN	O
the	DT	O
granules	NNS	O
with	IN	O
the	DT	O
cell	NN	O
surface	NN	O
membrane	NN	O
,	,	O
leading	VBG	O
to	TO	O
the	DT	O
exocytosis	NN	O
of	IN	O
the	DT	O
granule	NN	O
contents	NNS	O
,	,	O
such	JJ	O
as	IN	O
histamine	NN	O
,	,	O
cytokines	NNS	O
,	,	O
and	CC	O
leukotrienes	NNS	O
into	IN	O
the	DT	O
surrounding	VBG	O
tissue	NN	O
,	,	O
and	CC	O
the	DT	O
concomitant	JJ	O
induction	NN	O
of	IN	O
allergic	NN	O
symptoms	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
the	DT	O
activity	NN	O
of	IN	O
these	DT	O
substances	NNS	O
which	WDT	O
is	VBZ	O
responsible	JJ	O
for	IN	O
the	DT	O
clinical	JJ	O
symptoms	NNS	O
typical	JJ	O
of	IN	O
immediate	JJ	O
hypersensitivity	NN	O
.	.	O
These	DT	O
include	VBP	O
contraction	NN	O
of	IN	O
smooth	JJ	O
muscle	NN	O
in	IN	O
the	DT	O
airways	NNS	O
or	CC	O
the	DT	O
intestine	NN	O
,	,	O
the	DT	O
dilation	NN	O
of	IN	O
small	JJ	O
blood	NN	O
vessels	NNS	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
their	PRP$	O
permeability	NN	O
to	TO	O
water	NN	O
and	CC	O
plasma	NN	O
proteins	NNS	O
,	,	O
the	DT	O
secretion	NN	O
of	IN	O
thick	JJ	O
sticky	JJ	O
mucus	NN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
skin	NN	O
,	,	O
swelling	VBG	O
and	CC	O
the	DT	O
stimulation	NN	O
of	IN	O
nerve	NN	O
endings	NNS	O
that	WDT	O
results	NNS	O
in	IN	O
itching	VBG	O
.	.	O
Delayed	NNP	O
type	NN	O
hypersensitivity	NN	O
(	(	O
DTH	NNP	O
)	)	O
reactions	NNS	O
are	VBP	O
mediated	VBN	O
by	IN	O
T-cells	NNP	O
and	CC	O
macrophages	NNS	O
and	CC	O
become	VB	O
evident	JJ	O
only	RB	O
after	IN	O
1	CD	O
to	TO	O
2	CD	O
days	NNS	O
and	CC	O
persist	NN	O
from	IN	O
several	JJ	O
days	NNS	O
to	TO	O
a	DT	O
few	JJ	O
weeks	NNS	O
.	.	O
DTH	NNP	O
is	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
cell-mediated	JJ	O
hypersensitivity	NN	O
(	(	O
i.e.	JJ	O
,	,	O
T-cell	NNP	O
mediated	VBD	O
)	)	O
and	CC	O
is	VBZ	O
part	NN	O
of	IN	O
a	DT	O
larger	JJR	O
group	NN	O
of	IN	O
reactions	NNS	O
called	VBN	O
cell-mediated	JJ	O
immunity	NN	O
.	.	O
Anaphylaxis	NNP	O
,	,	O
or	CC	O
anaphylactic	JJ	O
shock	NN	O
,	,	O
is	VBZ	O
an	DT	O
acute	JJ	O
systemic	NN	O
(	(	O
whole	JJ	O
body	NN	O
)	)	O
type	NN	O
of	IN	O
allergic	JJ	O
reaction	NN	O
,	,	O
It	PRP	O
occurs	VBZ	O
when	WRB	O
a	DT	O
person	NN	O
has	VBZ	O
become	VBN	O
sensitized	VBN	O
to	TO	O
a	DT	O
certain	JJ	O
substance	NN	O
or	CC	O
allergen	NN	O
(	(	O
that	WDT	O
is	VBZ	O
,	,	O
the	DT	O
immune	NN	O
system	NN	O
has	VBZ	O
been	VBN	O
abnormally	RB	O
triggered	VBN	O
to	TO	O
recognize	VB	O
that	DT	O
allergen	NN	O
as	IN	O
a	DT	O
threat	NN	O
to	TO	O
the	DT	O
body	NN	O
)	)	O
.	.	O
On	IN	O
the	DT	O
second	JJ	O
or	CC	O
subsequent	JJ	O
exposure	NN	O
to	TO	O
the	DT	O
substance	NN	O
,	,	O
an	DT	O
allergic	JJ	O
reaction	NN	O
occurs	NNS	O
.	.	O
This	DT	O
reaction	NN	O
is	VBZ	O
sudden	JJ	O
,	,	O
severe	JJ	O
,	,	O
and	CC	O
involves	VBZ	O
the	DT	O
whole	JJ	O
body	NN	O
.	.	O
Anaphylaxis	NNP	O
is	VBZ	O
life-threatening	JJ	O
and	CC	O
can	MD	O
occur	VB	O
at	IN	O
any	DT	O
time	NN	O
.	.	O
Therapeutically	RB	O
,	,	O
many	JJ	O
agents	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
try	VB	O
to	TO	O
prevent	VB	O
the	DT	O
release	NN	O
of	IN	O
mediators	NNS	O
from	IN	O
mast	NN	O
cells	NNS	O
and	CC	O
basophils	NNS	O
and/or	VBP	O
to	TO	O
treat	VB	O
the	DT	O
downstream	NN	O
events	NNS	O
by	IN	O
blocking	VBG	O
or	CC	O
ameliorating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
mediators	NNS	O
on	IN	O
target	NN	O
tissues	NNS	O
.	.	O
Therapeutic	JJ	O
agents	NNS	O
commonly	RB	O
employed	VBP	O
fall	NN	O
under	IN	O
the	DT	O
following	JJ	O
main	JJ	O
groups	NNS	O
.	.	O
Antihistamines	NNS	O
block	NN	O
and	CC	O
mop	VB	O
up	RP	O
the	DT	O
released	VBN	O
histamine	NN	O
,	,	O
i.e	NN	O
.	.	O
the	DT	O
major	JJ	O
mediator	NN	O
of	IN	O
the	DT	O
allergic	JJ	O
response	NN	O
.	.	O
Alpha-1	JJ	O
beta	NN	O
-2	NN	O
agonists	NNS	O
,	,	O
e.g.	NN	O
,	,	O
Epinephrine	NNP	O
,	,	O
Salbutamol	NNP	O
overcome	VBP	O
indirectly	RB	O
the	DT	O
downstream	NN	O
effects	NNS	O
on	IN	O
vasculature	NN	O
and	CC	O
smooth	JJ	O
muscle	NN	O
.	.	O
Chromoglycate	NNP	O
is	VBZ	O
useful	JJ	O
for	IN	O
primary	JJ	O
prevention	NN	O
of	IN	O
mast	NN	O
cells/basophil	NN	O
degranulation	NN	O
.	.	O
This	DT	O
prophylactic	JJ	O
must	MD	O
be	VB	O
taken	VBN	O
continuously	RB	O
.	.	O
It	PRP	O
does	VBZ	O
not	RB	O
prevent	VB	O
the	DT	O
cross-linking	NN	O
of	IN	O
IgE	NNP	O
but	CC	O
it	PRP	O
somehow	RB	O
interferes	VBZ	O
with	IN	O
subsequent	JJ	O
events	NNS	O
.	.	O
Theophylline	NN	O
and	CC	O
other	JJ	O
phosphodiesterase	NN	O
inhibitors	NNS	O
again	RB	O
influence	VBP	O
downstream	JJ	O
biochemical	JJ	O
events	NNS	O
particularly	RB	O
associated	VBN	O
with	IN	O
cyclic	JJ	O
nucleotides	NNS	O
.	.	O
Steroids	NNS	O
have	VBP	O
multiple	JJ	O
sites	NNS	O
of	IN	O
activities	NNS	O
against	IN	O
the	DT	O
allergic	JJ	O
response	NN	O
.	.	O
They	PRP	O
are	VBP	O
either	DT	O
administered	VBN	O
locally	RB	O
and/or	JJ	O
systemically	RB	O
.	.	O
None	NN	O
of	IN	O
the	DT	O
above	JJ	O
treatments	NNS	O
are	VBP	O
ideal	JJ	O
for	IN	O
the	DT	O
modulation	NN	O
of	IN	O
allergic	JJ	O
responses	NNS	O
because	IN	O
each	DT	O
has	VBZ	O
specific	JJ	O
problems	NNS	O
such	JJ	O
as	IN	O
side	JJ	O
effects	NNS	O
including	VBG	O
drowsiness	NN	O
,	,	O
they	PRP	O
also	RB	O
lack	VBP	O
specificity	NN	O
in	IN	O
the	DT	O
immune	NN	O
system	NN	O
leading	VBG	O
to	TO	O
global	JJ	O
immuno-suppression	NN	O
.	.	O
Also	RB	O
many	JJ	O
of	IN	O
these	DT	O
therapeutic	JJ	O
agents	NNS	O
need	VBP	O
to	TO	O
be	VB	O
administered	VBN	O
continuously	RB	O
.	.	O
Therefore	RB	O
,	,	O
new	JJ	O
improved	VBN	O
treatments	NNS	O
are	VBP	O
constantly	RB	O
being	VBG	O
sought	VBN	O
to	TO	O
control	VB	O
the	DT	O
allergic	JJ	O
response	NN	O
prophylactically	RB	O
and/or	VBZ	O
therapeutically	RB	O
without	IN	O
the	DT	O
above-mentioned	JJ	O
limitations	NNS	O
.	.	O
Individuals	NNS	O
who	WP	O
wish	VBP	O
to	TO	O
become	VB	O
desensitized	VBN	O
against	IN	O
an	DT	O
allergen	NN	O
often	RB	O
must	MD	O
submit	VB	O
himself/herself	PRP	O
to	TO	O
injections	NNS	O
of	IN	O
measured	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
allergen	NN	O
,	,	O
first	RB	O
administered	VBN	O
at	IN	O
weekly	JJ	O
or	CC	O
biweekly	JJ	O
intervals	NNS	O
,	,	O
then	RB	O
gradually	RB	O
decreases	VBZ	O
to	TO	O
bimonthly	VB	O
or	CC	O
monthly	JJ	O
intervals	NNS	O
throughout	IN	O
the	DT	O
year	NN	O
.	.	O
Such	JJ	O
injections	NNS	O
generally	RB	O
commence	VBP	O
with	IN	O
a	DT	O
small	JJ	O
dose	NN	O
of	IN	O
the	DT	O
allergen	NN	O
and	CC	O
then	RB	O
gradually	RB	O
increasing	VBG	O
the	DT	O
dosage	NN	O
until	IN	O
a	DT	O
maximally-tolerated	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O
The	DT	O
individual	NN	O
is	VBZ	O
then	RB	O
kept	VBN	O
on	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
the	DT	O
allergen	NN	O
for	IN	O
long	JJ	O
periods	NNS	O
of	IN	O
time	NN	O
or	CC	O
until	IN	O
the	DT	O
individual	JJ	O
no	RB	O
longer	RBR	O
exhibits	VBZ	O
an	DT	O
allergic	JJ	O
reaction	NN	O
to	TO	O
the	DT	O
allergen	NN	O
.	.	O
Other	JJ	O
treatment	NN	O
regimes	NNS	O
have	VBP	O
been	VBN	O
devised	VBN	O
to	TO	O
reduce	VB	O
or	CC	O
eliminate	VB	O
an	DT	O
allergic	JJ	O
response	NN	O
.	.	O
Allergen	NNP	O
injection	NN	O
therapy	NN	O
(	(	O
allergen	JJ	O
immunotherapy	NN	O
also	RB	O
known	VBN	O
as	IN	O
subcutaneous	JJ	O
immunotherapy	NN	O
(	(	O
SCIT	NNP	O
)	)	O
is	VBZ	O
known	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
severity	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O
This	DT	O
treatment	NN	O
is	VBZ	O
theorized	VBN	O
to	TO	O
involve	VB	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
different	JJ	O
form	NN	O
of	IN	O
antibody	NN	O
,	,	O
a	DT	O
protective	NN	O
antibody	NN	O
which	WDT	O
is	VBZ	O
termed	VBN	O
a	DT	O
“	JJ	O
blocking	NN	O
antibody	NN	O
”	NNP	O
(	(	O
Cooke	NNP	B
,	,	I
R	NNP	I
A	NNP	I
et	NN	I
al.	NN	I
,	,	I
Serologic	NNP	I
Evidence	NNP	I
of	IN	I
Immunity	NNP	I
with	IN	I
Coexisting	NNP	I
Sensitization	NNP	I
in	IN	I
a	DT	I
Type	NN	I
of	IN	I
Human	NNP	I
Allergy	NNP	I
,	,	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
1935	CD	I
;	:	I
62:733	CD	I
)	)	O
.	.	O
Chemical	NNP	O
agents	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
which	WDT	O
inhibit	VBP	O
the	DT	O
interactions	NNS	O
between	IN	O
the	DT	O
IgE	NNP	O
and	CC	O
its	PRP$	O
receptor	NN	O
(	(	O
Cheng	NNP	O
et	RB	O
al.	RB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,965,605	CD	O
and	CC	O
Ra	NNP	O
et	VBP	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,090,034	CD	O
)	)	O
.	.	O
IgE	NNP	O
antagonists	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
used	VBN	O
to	TO	O
treat	VB	O
allergic	JJ	O
disease	NN	O
(	(	O
Presta	NNP	O
et	RB	O
al.	RB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
5,965,709	CD	O
)	)	O
and	CC	O
compounds	VBZ	O
that	DT	O
exhibit	NN	O
immunosuppressive	JJ	O
activity	NN	O
and	CC	O
inhibits	VBZ	O
the	DT	O
release	NN	O
of	IN	O
histamine	NN	O
(	(	O
Bycroft	NNP	B
et	RB	I
al.	RB	I
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,969,158	CD	O
)	)	O
.	.	O
St.	NNP	O
Remy	NNP	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,740,371	CD	O
,	,	O
discloses	VBZ	O
an	DT	O
immune	JJ	O
complex	NN	O
of	IN	O
an	DT	O
allergen	NN	O
for	IN	O
treating	VBG	O
allergies	NNS	O
involving	VBG	O
a	DT	O
combination	NN	O
of	IN	O
the	DT	O
specific	JJ	O
allergen	NN	O
and	CC	O
the	DT	O
corresponding	JJ	O
antibody	NN	O
to	TO	O
that	DT	O
allergen	NN	O
.	.	O
The	DT	O
injection	NN	O
of	IN	O
the	DT	O
complex	JJ	O
into	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
reduce	VB	O
a	DT	O
patient	NN	O
's	POS	O
allergic	JJ	O
reaction	NN	O
to	TO	O
that	DT	O
specific	JJ	O
allergen	NN	O
.	.	O
Others	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
certain	JJ	O
human	JJ	O
proteins	NNS	O
can	MD	O
neutralize	VB	O
IgE	NNP	O
by	IN	O
blocking	VBG	O
it	PRP	O
from	IN	O
interacting	VBG	O
with	IN	O
the	DT	O
mast	NN	O
cells	NNS	O
,	,	O
but	CC	O
this	DT	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
clearly	RB	O
as	IN	O
a	DT	O
clinically	RB	O
effective	JJ	O
therapy	NN	O
(	(	O
Stanworth	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Allergy	NNP	I
Treatment	NNP	I
with	IN	I
a	DT	I
Peptide	NNP	I
Vaccine	NNP	I
,	,	I
Lancet	NNP	I
1990	CD	I
;	:	I
336:1279-81	JJ	I
)	)	O
.	.	O
Patterson	NNP	O
et	CC	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,314,690	CD	O
disclosed	VBD	O
a	DT	O
method	NN	O
and	CC	O
preparations	NNS	O
for	IN	O
reducing	VBG	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
allergens	NNS	O
in	IN	O
allergic	JJ	O
subjects	NNS	O
wherein	VBP	O
substance	NN	O
P	NNP	O
(	(	O
a	DT	O
neuropeptide	NN	O
)	)	O
and	CC	O
an	DT	O
allergen	NN	O
or	CC	O
fragments	NNS	O
of	IN	O
allergens	NNS	O
or	CC	O
haptens	NNS	O
acting	VBG	O
as	IN	O
allergens	NNS	O
are	VBP	O
administered	VBN	O
together	RB	O
to	TO	O
the	DT	O
allergic	JJ	O
subjects	NNS	O
through	IN	O
a	DT	O
non-oral	JJ	O
route	NN	O
.	.	O
Cholera	NNP	O
Toxin	NNP	O
and	CC	O
B	NNP	O
Subunit	NNP	O
as	IN	O
Adjuvants	NNP	O
Cholera	NNP	O
toxin	NN	O
(	(	O
CT	NNP	O
)	)	O
and	CC	O
the	DT	O
closely	RB	O
related	JJ	O
heat-labile	JJ	O
toxin	NN	O
(	(	O
LT	NNP	O
)	)	O
from	IN	O
Escherichia	NNP	O
coli	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
exceptionally	RB	O
potent	JJ	O
immunoadjuvants	NNS	O
when	WRB	O
co-administered	JJ	O
with	IN	O
antigens	NNS	O
by	IN	O
various	JJ	O
mucosal	NN	O
routes	NNS	O
(	(	O
Elson	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
1984	CD	I
;	:	I
133:2892-2897	JJ	I
;	:	O
Hohngren	NNP	B
et	FW	I
al.	NN	I
,	,	I
Vaccin	NNP	I
1973	CD	I
;	:	I
1	CD	I
1	CD	I
:	:	I
1	CD	I
179-1184	JJ	I
;	:	O
Lycke	NNP	B
et	FW	I
al	NN	I
,	,	I
Eur	NNP	I
.	.	I
J.	NNP	I
Immunol	NNP	I
.	.	I
1992	CD	I
;	:	I
22:2277-228	JJ	I
1	CD	I
.	.	O
Both	DT	O
CT	NNP	O
and	CC	O
LT	NNP	O
are	VBP	O
recognized	VBN	O
as	IN	O
“	NN	O
AB	NNP	O
”	NNP	O
toxins	VBZ	O
in	IN	O
that	DT	O
they	PRP	O
are	VBP	O
composed	VBN	O
of	IN	O
two	CD	O
distinct	JJ	O
structural	JJ	O
and	CC	O
functional	JJ	O
components	NNS	O
:	:	O
a	DT	O
single	JJ	O
toxic-active	JJ	O
A	NNP	O
subunit	NN	O
component	NN	O
and	CC	O
a	DT	O
non-toxic	JJ	O
cell-binding	NN	O
B	NNP	O
subunit	NN	O
.	.	O
The	DT	O
latter	NN	O
is	VBZ	O
a	DT	O
imopentamer	JJ	O
component	NN	O
and	CC	O
a	DT	O
non-toxic	JJ	O
affinity	NN	O
for	IN	O
GMI	NNP	O
ganglioside	NN	O
receptors	NNS	O
(	(	O
Holingren	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nature	NNP	I
19	CD	I
8	CD	I
1	CD	I
;	:	I
292:413-417	JJ	I
)	)	O
.	.	O
Such	JJ	O
receptors	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
be	VB	O
present	JJ	O
on	IN	O
most	JJS	O
mammalian	JJ	O
cells	NNS	O
,	,	O
e.g.	NN	O
,	,	O
on	IN	O
skin	NN	O
and	CC	O
other	JJ	O
epithelial	JJ	O
cells	NNS	O
,	,	O
on	IN	O
all	DT	O
known	VBN	O
antigen-presenting	JJ	O
cells	NNS	O
including	VBG	O
dendritic	JJ	O
cells	NNS	O
(	(	O
DC	NNP	O
)	)	O
and	CC	O
Langerhan	NNP	O
's	POS	O
cells	NNS	O
(	(	O
LC	NNP	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
B	NNP	O
and	CC	O
T	NNP	O
lymphocytes	NNS	O
.	.	O
Recently	RB	O
,	,	O
Gleim	NNP	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,980,898	CD	O
disclosed	VBD	O
a	DT	O
system	NN	O
for	IN	O
transcutaneous	JJ	O
immunization	NN	O
that	WDT	O
induces	VBZ	O
an	DT	O
immune	JJ	O
response	NN	O
(	(	O
e.g.	JJ	O
,	,	O
humoral	JJ	O
and/or	NN	O
cellular	JJ	O
effectors	NNS	O
)	)	O
in	IN	O
an	DT	O
animal	NN	O
or	CC	O
human	NN	O
.	.	O
The	DT	O
system	NN	O
provides	VBZ	O
a	DT	O
simple	JJ	O
application	NN	O
to	TO	O
intact	JJ	O
skin	NN	O
of	IN	O
both	DT	O
rodents	NNS	O
and	CC	O
humans	NNS	O
of	IN	O
a	DT	O
formulation	NN	O
comprised	VBN	O
of	IN	O
antigen	NN	O
and	CC	O
an	DT	O
adjuvant	NN	O
that	WDT	O
was	VBD	O
whole	JJ	O
cholera	NN	O
toxin	NN	O
.	.	O
Common	JJ	O
to	TO	O
allergies	NNS	O
is	VBZ	O
the	DT	O
involvement	NN	O
of	IN	O
the	DT	O
IgE	NNP	O
class	NN	O
of	IN	O
antibody	NN	O
.	.	O
Individuals	NNS	O
are	VBP	O
not	RB	O
born	VBN	O
with	IN	O
allergies	NNS	O
;	:	O
rather	RB	O
they	PRP	O
acquire	VB	O
them	PRP	O
by	IN	O
exposure	NN	O
to	TO	O
allergens	NNS	O
.	.	O
The	DT	O
steps	NNS	O
of	IN	O
the	DT	O
IgE	NNP	O
allergic	JJ	O
reaction	NN	O
are	VBP	O
sensitization	NN	O
upon	IN	O
first	JJ	O
exposure	NN	O
to	TO	O
the	DT	O
allergen	NN	O
,	,	O
and	CC	O
then	RB	O
the	DT	O
allergic	JJ	O
response	NN	O
to	TO	O
subsequent	JJ	O
exposures	NNS	O
.	.	O
The	DT	O
allergic	JJ	O
response	NN	O
consists	VBZ	O
of	IN	O
an	DT	O
immediate	JJ	O
and	CC	O
delayed	JJ	O
response	NN	O
referred	VBD	O
to	TO	O
as	IN	O
the	DT	O
early	JJ	O
and	CC	O
late	JJ	O
phase	NN	O
responses	NNS	O
respectively	RB	O
.	.	O
In	IN	O
atopic	JJ	O
individuals	NNS	O
,	,	O
those	DT	O
prone	NN	O
to	TO	O
allergies	NNS	O
,	,	O
the	DT	O
initial	JJ	O
exposure	NN	O
to	TO	O
an	DT	O
antigen	NN	O
results	NNS	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
IgE	NNP	O
antibodies	NNS	O
that	WDT	O
specifically	RB	O
recognize	VBP	O
that	IN	O
allergen	NN	O
.	.	O
This	DT	O
process	NN	O
is	VBZ	O
called	VBN	O
sensitization	NN	O
.	.	O
The	DT	O
early	JJ	O
phase	NN	O
response	NN	O
(	(	O
ERP	NNP	O
)	)	O
is	VBZ	O
the	DT	O
immediate	JJ	O
reaction	NN	O
that	WDT	O
occurs	VBZ	O
within	IN	O
minutes	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
an	DT	O
allergen	NN	O
.	.	O
IgE	NNP	O
are	VBP	O
bound	VBN	O
to	TO	O
the	DT	O
surface	NN	O
of	IN	O
a	DT	O
neuroimmune	NN	O
cell	NN	O
called	VBD	O
the	DT	O
mast	NN	O
cell	NN	O
(	(	O
in	IN	O
the	DT	O
circulation	NN	O
these	DT	O
cells	NNS	O
are	VBP	O
called	VBN	O
basophils	NNS	O
)	)	O
.	.	O
Sufficient	JJ	O
numbers	NNS	O
of	IN	O
bound	NN	O
IgE	NNP	O
antibodies	VBZ	O
that	IN	O
react	NN	O
with	IN	O
an	DT	O
allergen	NN	O
causes	VBZ	O
the	DT	O
mast	NN	O
cell	NN	O
to	TO	O
release	VB	O
its	PRP$	O
content	NN	O
of	IN	O
secretory	JJ	O
vesicles	NNS	O
,	,	O
a	DT	O
process	NN	O
known	VBN	O
as	IN	O
degranulation	NN	O
.	.	O
The	DT	O
secretory	NN	O
vesicles	NNS	O
contain	VBP	O
histamine	NN	O
and	CC	O
other	JJ	O
stored	JJ	O
substances	NNS	O
such	JJ	O
as	IN	O
nerve	NN	O
growth	NN	O
factor	NN	O
(	(	O
NGF	NNP	O
)	)	O
.	.	O
In	IN	O
addition	NN	O
the	DT	O
mast	NN	O
cell	NN	O
and	CC	O
T	NNP	O
cells	NNS	O
immediately	RB	O
begin	VBP	O
manufacturing	VBG	O
leukotrienes	NNS	O
,	,	O
cytokines	NNS	O
,	,	O
enzymes	NNS	O
and	CC	O
substances	NNS	O
that	WDT	O
activate	VBP	O
blood	NN	O
platelets	NNS	O
and	CC	O
attract	JJ	O
secondary	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
eosinophils	NNS	O
.	.	O
Symptoms	NNS	O
vary	VBP	O
depending	VBG	O
on	IN	O
the	DT	O
site	NN	O
,	,	O
but	CC	O
common	JJ	O
reactions	NNS	O
are	VBP	O
smooth	JJ	O
muscle	NN	O
contraction	NN	O
,	,	O
mucus	NN	O
secretion	NN	O
,	,	O
vascular	JJ	O
permeability	NN	O
,	,	O
and	CC	O
sensory	JJ	O
nerve	NN	O
stimulation	NN	O
.	.	O
The	DT	O
late	JJ	O
phase	NN	O
response	NN	O
(	(	O
LPR	NNP	O
)	)	O
develops	VBZ	O
over	IN	O
hours	NNS	O
to	TO	O
days	NNS	O
of	IN	O
exposure	NN	O
as	IN	O
eosinophils	NNS	O
and	CC	O
other	JJ	O
cells	NNS	O
are	VBP	O
attracted	VBN	O
to	TO	O
the	DT	O
area	NN	O
.	.	O
Eosinophils	NNS	O
produce	VBP	O
major	JJ	O
basic	JJ	O
protein	NN	O
,	,	O
eosinophil	JJ	O
cationic	JJ	O
protein	NN	O
,	,	O
leukotrienes	NNS	O
and	CC	O
nerve	NN	O
growth	NN	O
factor	NN	O
.	.	O
TH2	NNP	O
lymphocytes	VBZ	O
release	NN	O
cytokines	NNS	O
that	WDT	O
promote	VBP	O
further	JJ	O
IgE	NNP	O
production	NN	O
and	CC	O
eosinophil	JJ	O
chemo	NN	O
attraction	NN	O
,	,	O
and	CC	O
increased	VBD	O
numbers	NNS	O
of	IN	O
mast	NN	O
cells	NNS	O
.	.	O
Nerve	NNP	O
Involvement	NNP	O
in	IN	O
Allergy	NNP	O
The	DT	O
sensory	JJ	O
nerve	NN	O
stimulation	NN	O
causes	VBZ	O
reflexes	NNS	O
that	WDT	O
are	VBP	O
designed	VBN	O
to	TO	O
aid	VB	O
in	IN	O
defending	VBG	O
the	DT	O
tissue	NN	O
.	.	O
These	DT	O
reflexes	NNS	O
are	VBP	O
often	RB	O
a	DT	O
larger	JJR	O
problem	NN	O
then	RB	O
the	DT	O
local	JJ	O
allergic	NN	O
response	NN	O
.	.	O
Reflexes	NNS	O
can	MD	O
range	VB	O
from	IN	O
large	JJ	O
gross	JJ	O
motor	NN	O
actions	NNS	O
to	TO	O
regional	JJ	O
afferent	NN	O
and	CC	O
efferent	JJ	O
arcs	NN	O
or	CC	O
even	RB	O
local	JJ	O
axon-axonal	JJ	O
reflexes	NNS	O
involving	VBG	O
a	DT	O
single	JJ	O
neuron	NN	O
.	.	O
Some	DT	O
reflexes	NNS	O
recruit	VBP	O
major	JJ	O
motor	NN	O
actions	NNS	O
that	WDT	O
are	VBP	O
well	RB	O
recognized	VBN	O
.	.	O
In	IN	O
the	DT	O
nose	NN	O
,	,	O
sneezing	NN	O
is	VBZ	O
a	DT	O
reflex	JJ	O
attempt	NN	O
to	TO	O
expel	VB	O
unwanted	JJ	O
material	NN	O
and	CC	O
coughing	NN	O
is	VBZ	O
the	DT	O
equivalent	JJ	O
response	NN	O
in	IN	O
the	DT	O
lungs	NNS	O
.	.	O
Regional	JJ	O
reflex	NN	O
arcs	NN	O
involve	VBP	O
the	DT	O
sensing	NN	O
of	IN	O
the	DT	O
stimulus	NN	O
by	IN	O
the	DT	O
sensory	JJ	O
neuron	NN	O
,	,	O
the	DT	O
transfer	NN	O
of	IN	O
the	DT	O
message	NN	O
to	TO	O
the	DT	O
ganglia	NN	O
and	CC	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
and	CC	O
an	DT	O
efferent	JJ	O
response	NN	O
via	IN	O
autonomic	JJ	O
neurons	NNS	O
.	.	O
Reflex	NNP	O
excitation	NN	O
by	IN	O
the	DT	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
directly	RB	O
causes	VBZ	O
mast	NN	O
cell	NN	O
to	TO	O
degranulate	VB	O
,	,	O
thereby	RB	O
spreading	VBG	O
the	DT	O
reaction	NN	O
.	.	O
In	IN	O
addition	NN	O
these	DT	O
reflexes	NNS	O
control	VBP	O
a	DT	O
variety	NN	O
of	IN	O
other	JJ	O
functions	NNS	O
.	.	O
In	IN	O
the	DT	O
nose	JJ	O
these	DT	O
reflexes	NNS	O
cause	VBP	O
increased	JJ	O
mucus	NN	O
production	NN	O
,	,	O
increased	VBD	O
cilia	JJ	O
movement	NN	O
,	,	O
nasal	JJ	O
congestion	NN	O
and	CC	O
sneezing	NN	O
.	.	O
In	IN	O
the	DT	O
lungs	NNS	O
reflexes	VBP	O
cause	NN	O
bronchospasm	NN	O
,	,	O
increased	VBD	O
mucosal	NN	O
congestion	NN	O
,	,	O
production	NN	O
of	IN	O
airway	JJ	O
secretions	NNS	O
and	CC	O
coughing	NN	O
.	.	O
In	IN	O
the	DT	O
GI	NNP	O
tract	NN	O
reflexes	NNS	O
cause	VBP	O
dysmotility	NN	O
,	,	O
mucosal	JJ	O
congestion	NN	O
and	CC	O
secretions	NNS	O
.	.	O
In	IN	O
the	DT	O
skin	NN	O
the	DT	O
reflexes	NNS	O
cause	VBP	O
swelling	VBG	O
and	CC	O
itching	VBG	O
.	.	O
Finally	RB	O
there	EX	O
are	VBP	O
local	JJ	O
axon-axonal	JJ	O
reflexes	NNS	O
in	IN	O
sensory	JJ	O
nociceptive	JJ	O
nerve	NN	O
fibers	NNS	O
.	.	O
Allergic	NNP	O
stimulation	NN	O
of	IN	O
a	DT	O
single	JJ	O
neuron	NN	O
causes	VBZ	O
release	NN	O
of	IN	O
mediators	NNS	O
from	IN	O
other	JJ	O
axons	NNS	O
of	IN	O
the	DT	O
same	JJ	O
neuron	NN	O
.	.	O
(	(	O
Barnes	NNPS	B
P	NNP	I
et	CC	I
al	NN	I
.	.	I
1991	CD	I
Neuropeptides	NNP	I
in	IN	I
the	DT	I
respiratory	NN	I
tract	NN	I
.	.	I
Am	NNP	I
Rev	NNP	I
Resp	NNP	I
Dis	NNP	I
144:1187-1198	JJ	I
,	,	I
1391-1399	JJ	I
)	)	O
In	IN	O
chronic	JJ	O
allergic	JJ	O
stimulation	NN	O
the	DT	O
mast	NN	O
cells	NNS	O
and	CC	O
eosinophils	NNS	O
releases	NNS	O
nerve	VBP	O
growth	NN	O
factor	NN	O
which	WDT	O
causes	VBZ	O
growth	NN	O
of	IN	O
the	DT	O
nerves	NNS	O
in	IN	O
the	DT	O
region	NN	O
.	.	O
Thereby	RB	O
allowing	VBG	O
for	IN	O
increased	VBN	O
neural	JJ	O
responses	NNS	O
and	CC	O
hyper	JJ	O
reactivity	NN	O
.	.	O
This	DT	O
hyper	JJ	O
reactivity	NN	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
allergic	VB	O
reactions	NNS	O
but	CC	O
extends	VBZ	O
to	TO	O
non-allergic	JJ	O
conditions	NNS	O
such	JJ	O
as	IN	O
respiratory	JJ	O
tract	JJ	O
infections	NNS	O
including	VBG	O
viral	JJ	O
and	CC	O
bacterial	JJ	O
infections	NNS	O
.	.	O
Specifically	RB	O
viral	JJ	O
rhinitis	NN	O
,	,	O
viral	JJ	O
and	CC	O
bacterial	JJ	O
sinusitis	NN	O
,	,	O
suppurative	JJ	O
otitis	NN	O
media	NNS	O
,	,	O
bronchitis	NN	O
and	CC	O
pneumonia	NN	O
.	.	O
Therefore	RB	O
individuals	NNS	O
become	VBP	O
more	RBR	O
susceptible	JJ	O
to	TO	O
these	DT	O
conditions	NNS	O
and	CC	O
have	VBP	O
more	JJR	O
frequent	JJ	O
and	CC	O
severe	JJ	O
infections	NNS	O
.	.	O
Furthermore	RB	O
the	DT	O
repeated	VBN	O
allergic	JJ	O
reactions	NNS	O
cause	VBP	O
changes	NNS	O
in	IN	O
the	DT	O
qualitative	JJ	O
response	NN	O
of	IN	O
the	DT	O
neural	JJ	O
reflexes	NNS	O
such	JJ	O
that	IN	O
they	PRP	O
are	VBP	O
inappropriately	RB	O
activated	VBN	O
.	.	O
This	DT	O
negatively	JJ	O
effects	NNS	O
non-allergic	JJ	O
conditions	NNS	O
,	,	O
such	JJ	O
as	IN	O
bronchospasm	NN	O
mucus	NN	O
production	NN	O
and	CC	O
coughing	VBG	O
in	IN	O
non-allergic	JJ	O
lung	NN	O
conditions	NNS	O
such	JJ	O
as	IN	O
bronchitis	NN	O
and	CC	O
emphysema	NN	O
.	.	O
Allergic	NNP	O
Reactions	NNP	O
Differ	NNP	O
from	IN	O
Inflammatory	NNP	O
Reactions	NNP	O
Allergic	NNP	O
reactions	NNS	O
differ	VBP	O
from	IN	O
inflammation	NN	O
.	.	O
Allergies	NNS	O
represent	VBP	O
the	DT	O
body	NN	O
's	POS	O
inappropriate	JJ	O
response	NN	O
to	TO	O
what	WP	O
is	VBZ	O
in	IN	O
essence	NN	O
a	DT	O
harmless	NN	O
antigen	NN	O
.	.	O
It	PRP	O
is	VBZ	O
believed	VBN	O
that	IN	O
the	DT	O
IgE	NNP	O
allergic	JJ	O
reactions	NNS	O
evolved	VBD	O
to	TO	O
combat	VB	O
parasitic	JJ	O
infections	NNS	O
which	WDT	O
are	VBP	O
now	RB	O
rare	JJ	O
in	IN	O
industrialized	JJ	O
societies	NNS	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
inflammation	NN	O
is	VBZ	O
the	DT	O
body	NN	O
's	POS	O
response	NN	O
to	TO	O
actual	JJ	O
tissue	NN	O
damage	NN	O
or	CC	O
infection	NN	O
.	.	O
Inflammation	NN	O
is	VBZ	O
clinically	RB	O
distinguished	VBN	O
by	IN	O
the	DT	O
classical	JJ	O
symptoms	NNS	O
of	IN	O
calor	NN	O
,	,	O
rubor	NN	O
and	CC	O
dolor	NN	O
:	:	O
heat	NN	O
,	,	O
redness	NN	O
and	CC	O
pain	NN	O
.	.	O
Inflammation	NN	O
is	VBZ	O
a	DT	O
process	NN	O
that	WDT	O
triggers	VBZ	O
a	DT	O
cascade	NN	O
of	IN	O
mediators	NNS	O
with	IN	O
wide	JJ	O
effects	NNS	O
,	,	O
both	DT	O
locally	RB	O
and	CC	O
systemically	RB	O
.	.	O
Local	JJ	O
reactions	NNS	O
include	VBP	O
pain	NN	O
,	,	O
vasodilation	NN	O
and	CC	O
migration	NN	O
of	IN	O
macrophages	NNS	O
and	CC	O
neutrophils	NNS	O
.	.	O
Systemic	JJ	O
reactions	NNS	O
include	VBP	O
fever	NN	O
.	.	O
Certain	NNP	O
conditions	NNS	O
,	,	O
such	JJ	O
as	IN	O
rhinitis	NN	O
or	CC	O
asthma	NN	O
,	,	O
can	MD	O
be	VB	O
triggered	VBN	O
by	IN	O
allergies	NNS	O
,	,	O
infections	NNS	O
,	,	O
irritating	VBG	O
chemicals	NNS	O
or	CC	O
may	MD	O
be	VB	O
entirely	RB	O
neurogenic	JJ	O
,	,	O
the	DT	O
result	NN	O
of	IN	O
nerve	NN	O
activity	NN	O
without	IN	O
prior	JJ	O
inflammatory	NN	O
or	CC	O
allergic	JJ	O
stimulation	NN	O
.	.	O
Specific	JJ	O
Allergic	NNP	O
Conditions	NNP	O
Rhinitis	NNP	O
Allergic	NNP	O
Rhinitis	NNP	O
The	DT	O
inner	JJ	O
lining	NN	O
of	IN	O
the	DT	O
nose	NN	O
is	VBZ	O
a	DT	O
mucosa	NN	O
that	WDT	O
contains	VBZ	O
serous	JJ	O
and	CC	O
mucus	VB	O
glands	NNS	O
and	CC	O
large	JJ	O
numbers	NNS	O
of	IN	O
mast	NN	O
cells	NNS	O
.	.	O
This	DT	O
mucosa	NN	O
extends	VBZ	O
to	TO	O
the	DT	O
openings	NNS	O
leading	VBG	O
to	TO	O
the	DT	O
sinuses	NNS	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
Eustachian	JJ	O
tube	NN	O
where	WRB	O
it	PRP	O
is	VBZ	O
continuous	JJ	O
with	IN	O
the	DT	O
mucosa	NN	O
of	IN	O
the	DT	O
sinuses	NNS	O
and	CC	O
middle	JJ	O
ear	NN	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
EPR	NNP	O
of	IN	O
the	DT	O
nasal	NN	O
mucosa	NN	O
causes	VBZ	O
mast	RBS	O
cell	JJ	O
degranulation	NN	O
.	.	O
The	DT	O
release	NN	O
of	IN	O
histamine	NN	O
,	,	O
heparin	NN	O
and	CC	O
neuropeptides	NNS	O
provokes	NNS	O
vasodilation	NN	O
and	CC	O
acute	JJ	O
swelling	NN	O
of	IN	O
the	DT	O
mucosa	NN	O
and	CC	O
has	VBZ	O
some	DT	O
minor	JJ	O
direct	JJ	O
stimulatory	NN	O
effect	NN	O
on	IN	O
the	DT	O
mucus	NN	O
secreting	VBG	O
glands	NNS	O
.	.	O
Reflex	NNP	O
excitation	NN	O
causes	VBZ	O
reflex	JJ	O
sneezing	NN	O
,	,	O
congestion	NN	O
and	CC	O
neural	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
seromucinous	JJ	O
glands	NNS	O
and	CC	O
further	JJ	O
congestion	NN	O
.	.	O
LPR	NNP	O
attracts	VBZ	O
eosinophils	NNS	O
and	CC	O
prolongs	VBZ	O
the	DT	O
reaction	NN	O
.	.	O
Allergic	JJ	O
reactions	NNS	O
can	MD	O
also	RB	O
be	VB	O
chronic	JJ	O
,	,	O
a	DT	O
condition	NN	O
known	VBN	O
as	IN	O
perennial	JJ	O
rhinitis	NN	O
.	.	O
In	IN	O
these	DT	O
cases	NNS	O
airborne	VBP	O
allergens	NNS	O
are	VBP	O
constantly	RB	O
in	IN	O
the	DT	O
environment	NN	O
.	.	O
Chronic	JJ	O
low-level	JJ	O
allergic	JJ	O
reactions	NNS	O
cause	VBP	O
a	DT	O
thickening	NN	O
of	IN	O
the	DT	O
nasal	JJ	O
mucosa	NN	O
due	JJ	O
to	TO	O
edema	VB	O
and	CC	O
hypertrophy	NN	O
of	IN	O
glandular	JJ	O
elements	NNS	O
.	.	O
As	IN	O
a	DT	O
result	NN	O
the	DT	O
primary	JJ	O
symptoms	NNS	O
of	IN	O
perennial	JJ	O
rhinitis	NN	O
are	VBP	O
nasal	JJ	O
congestion	NN	O
,	,	O
and	CC	O
postnasal	NN	O
drip	NN	O
.	.	O
After	IN	O
each	DT	O
allergic	JJ	O
reaction	NN	O
the	DT	O
mucosa	NN	O
swells	VBZ	O
;	:	O
repeated	VBN	O
allergic	JJ	O
reactions	NNS	O
enlarges	VBZ	O
the	DT	O
mucosa	NN	O
permanently	RB	O
and	CC	O
may	MD	O
form	VB	O
polyps	NNS	O
.	.	O
Thickening	NN	O
of	IN	O
the	DT	O
mucosa	NN	O
can	MD	O
cause	VB	O
obstruction	NN	O
of	IN	O
the	DT	O
small	JJ	O
openings	NNS	O
that	WDT	O
allow	VBP	O
drainage	NN	O
from	IN	O
the	DT	O
sinus	NN	O
.	.	O
Obstruction	NN	O
of	IN	O
these	DT	O
openings	NNS	O
allows	VBZ	O
nasal	JJ	O
secretions	NNS	O
to	TO	O
collect	VB	O
and	CC	O
become	VB	O
infected	JJ	O
,	,	O
thereby	RB	O
causing	VBG	O
sinusitis	NN	O
.	.	O
Topical	JJ	O
treatment	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
includes	VBZ	O
steroid	JJ	O
sprays	NNS	O
and	CC	O
chromalyn	JJ	O
sodium	NN	O
(	(	O
Nasocrom®	NNP	O
)	)	O
a	DT	O
chemical	NN	O
that	WDT	O
blocks	VBZ	O
mast	RBS	O
cell	NN	O
degranulation	NN	O
,	,	O
and/or	JJ	O
nasal	NN	O
decongestants	NNS	O
(	(	O
Neosynephrine	NNP	O
)	)	O
.	.	O
Systemic	NNP	O
treatment	NN	O
includes	VBZ	O
oral	JJ	O
anti-histamines	NNS	O
and	CC	O
non-sedating	JJ	O
antihistamines	NNS	O
(	(	O
Allegra®	NNP	O
,	,	O
Zyrtec®	NNP	O
,	,	O
Claritin®	NNP	O
)	)	O
.	.	O
Long-term	JJ	O
therapy	NN	O
requires	VBZ	O
immune	JJ	O
desensitization	NN	O
to	TO	O
the	DT	O
allergen	NN	O
by	IN	O
progressive	JJ	O
intradermal	JJ	O
injections	NNS	O
of	IN	O
the	DT	O
allergen	NN	O
over	IN	O
months	NNS	O
to	TO	O
years	NNS	O
.	.	O
rhinitis	NN	O
can	MD	O
lead	VB	O
Allergic	NNP	O
rhinitis	NN	O
can	MD	O
lead	VB	O
to	TO	O
pulmonary	JJ	O
disease	NN	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
asthma	VB	O
and	CC	O
emphysema	VB	O
,	,	O
suitably	RB	O
asthma	NN	O
caused	VBN	O
by	IN	O
hyperreactivity	NN	O
and/or	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
bronchoconstriction	NN	O
,	,	O
mucosal	NN	O
edema	NN	O
,	,	O
increased	VBD	O
secretions	NNS	O
and	CC	O
cough	NN	O
.	.	O
These	DT	O
can	MD	O
be	VB	O
treated	VBN	O
by	IN	O
the	DT	O
application	NN	O
of	IN	O
CnT	NNP	O
to	TO	O
the	DT	O
nasal	JJ	O
cavity	NN	O
of	IN	O
patients	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O
It	PRP	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
allergic	JJ	O
conditions	NNS	O
of	IN	O
the	DT	O
nose	JJ	O
can	MD	O
cause	VB	O
reflex	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
lung	NN	O
that	WDT	O
mimic	VBZ	O
or	CC	O
exacerbate	VB	O
asthma	NNS	O
.	.	O
(	(	O
McCusker	NNP	B
C	NNP	I
et	FW	I
al	NN	I
2002	CD	I
,	,	I
Site-specific	JJ	I
sensitization	NN	I
in	IN	I
a	DT	I
murine	JJ	I
model	NN	I
of	IN	I
allergic	JJ	I
rhinitis	NN	I
:	:	I
Role	NN	I
of	IN	I
the	DT	I
upper	JJ	I
airway	NN	I
in	IN	I
lower	JJR	I
airway	NN	I
disease	NN	I
,	,	I
J	NNP	I
Allergy	NNP	I
Clin	NNP	I
Immunol	NNP	I
,	,	I
110:891-898	JJ	I
)	)	O
Perennial	NNP	O
Allergic	NNP	O
Rhinitis	NNP	O
Perenial	NNP	O
rhinitis	NN	O
is	VBZ	O
a	DT	O
chronic	JJ	O
condition	NN	O
and	CC	O
certain	JJ	O
symptoms	NNS	O
,	,	O
such	JJ	O
as	IN	O
nasal	JJ	O
congestion	NN	O
,	,	O
are	VBP	O
more	RBR	O
prominent	JJ	O
then	RB	O
others	NNS	O
such	JJ	O
as	IN	O
sneezing	NN	O
.	.	O
Therefore	RB	O
therapy	NN	O
for	IN	O
this	DT	O
condition	NN	O
needs	VBZ	O
to	TO	O
be	VB	O
over	IN	O
more	JJR	O
prolonged	JJ	O
period	NN	O
,	,	O
if	IN	O
not	RB	O
indefinitely	RB	O
.	.	O
Although	IN	O
the	DT	O
same	JJ	O
treatments	NNS	O
as	IN	O
disclosed	VBN	O
for	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
can	MD	O
be	VB	O
used	VBN	O
repeatedly	RB	O
,	,	O
certain	JJ	O
methods	NNS	O
of	IN	O
treatment	NN	O
are	VBP	O
disclosed	VBN	O
here	RB	O
that	DT	O
are	VBP	O
more	RBR	O
efficient	JJ	O
and	CC	O
convenient	NN	O
for	IN	O
longer	JJR	O
term	NN	O
therapy	NN	O
.	.	O
Parasympathetic	JJ	O
neurons	NNS	O
do	VBP	O
not	RB	O
extend	VB	O
from	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
to	TO	O
their	PRP$	O
target	NN	O
organs	NNS	O
in	IN	O
the	DT	O
nose	NN	O
.	.	O
Instead	RB	O
parasympathetic	JJ	O
preganglionic	JJ	O
neurons	NNS	O
have	VBP	O
their	PRP$	O
cell	NN	O
bodies	NNS	O
in	IN	O
the	DT	O
brain	NN	O
stem	NN	O
and	CC	O
have	VBP	O
an	DT	O
axon	NN	O
that	WDT	O
extends	VBZ	O
partway	RB	O
and	CC	O
synapses	VBZ	O
on	IN	O
the	DT	O
cell	NN	O
body	NN	O
of	IN	O
a	DT	O
second	JJ	O
neuron	NN	O
called	VBD	O
the	DT	O
postganglionic	JJ	O
neuron	NN	O
.	.	O
The	DT	O
axons	NNS	O
of	IN	O
the	DT	O
postganglionic	JJ	O
neurons	NNS	O
extend	VBP	O
into	IN	O
nose	JJ	O
and	CC	O
sinuses	NNS	O
and	CC	O
modulate	VB	O
many	JJ	O
of	IN	O
the	DT	O
biological	JJ	O
responses	NNS	O
seen	VBN	O
during	IN	O
allergic	JJ	O
reactions	NNS	O
.	.	O
The	DT	O
cell	NN	O
body	NN	O
of	IN	O
the	DT	O
post	NN	O
ganglionic	JJ	O
parasympathetic	JJ	O
neuron	NN	O
also	RB	O
receives	VBZ	O
collateral	JJ	O
afferent	NN	O
synapses	NNS	O
from	IN	O
sensory	JJ	O
neurons	NNS	O
that	WDT	O
are	VBP	O
stimulated	VBN	O
during	IN	O
allergic	JJ	O
reactions	NNS	O
.	.	O
Therefore	RB	O
much	JJ	O
of	IN	O
the	DT	O
neuronal	JJ	O
circuit	NN	O
involved	VBN	O
in	IN	O
the	DT	O
allergic	JJ	O
reaction	NN	O
converges	NNS	O
onto	IN	O
the	DT	O
cell	NN	O
body	NN	O
of	IN	O
the	DT	O
postganglionic	JJ	O
neuron	NN	O
.	.	O
All	DT	O
of	IN	O
the	DT	O
postganglionic	JJ	O
neuron	NN	O
cell	NN	O
bodies	NNS	O
are	VBP	O
concentrated	VBN	O
in	IN	O
small	JJ	O
structure	NN	O
called	VBN	O
the	DT	O
sphenopalatine	NN	O
ganglion	NN	O
.	.	O
Moreover	RB	O
all	DT	O
afferent	JJ	O
synaptic	JJ	O
connections	NNS	O
on	IN	O
these	DT	O
neurons	NNS	O
is	VBZ	O
cholinergic	JJ	O
,	,	O
the	DT	O
neurotransmitter	NN	O
most	RBS	O
sensitive	JJ	O
to	TO	O
BoNT	NNP	O
.	.	O
Therefore	DT	O
application	NN	O
of	IN	O
CnT	NNP	O
to	TO	O
the	DT	O
sphenopalatine	JJ	O
ganglion	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
efficient	JJ	O
way	NN	O
of	IN	O
blocking	VBG	O
the	DT	O
allergic	JJ	O
neural	JJ	O
reaction	NN	O
.	.	O
The	DT	O
sphenopalatine	JJ	O
ganglion	NN	O
is	VBZ	O
accessible	JJ	O
to	TO	O
needle	VB	O
injection	NN	O
via	IN	O
the	DT	O
sphenopalatine	JJ	O
canal	NN	O
.	.	O
This	DT	O
canal	JJ	O
passes	NNS	O
though	IN	O
the	DT	O
hard	JJ	O
palate	NN	O
and	CC	O
is	VBZ	O
accessible	JJ	O
about	IN	O
one	CD	O
centimeter	NN	O
medial	NN	O
to	TO	O
the	DT	O
second	JJ	O
molar	NN	O
.	.	O
Injections	NNS	O
of	IN	O
anesthetic	JJ	O
and	CC	O
vasoconstrictor	NN	O
agents	NNS	O
are	VBP	O
commonly	RB	O
performed	VBN	O
by	IN	O
clinicians	NNS	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
of	IN	O
nasal	NN	O
surgery	NN	O
.	.	O
Infectious	JJ	O
Rhinitis	NNP	O
Although	IN	O
they	PRP	O
share	NN	O
some	DT	O
of	IN	O
the	DT	O
same	JJ	O
symptoms	NNS	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
differs	NNS	O
from	IN	O
infectious	JJ	O
rhinitis	NN	O
.	.	O
The	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
infectious	JJ	O
rhinitis	NN	O
is	VBZ	O
a	DT	O
viral	JJ	O
infection	NN	O
,	,	O
known	VBN	O
as	IN	O
the	DT	O
common	JJ	O
cold	NN	O
.	.	O
Bacterial	NNP	O
and	CC	O
fungal	JJ	O
infections	NNS	O
of	IN	O
the	DT	O
nose	JJ	O
occur	NN	O
also	RB	O
but	CC	O
these	DT	O
are	VBP	O
comparatively	RB	O
rare	JJ	O
as	IN	O
primary	JJ	O
events	NNS	O
.	.	O
During	IN	O
viral	JJ	O
infections	NNS	O
the	DT	O
epithelial	JJ	O
cells	NNS	O
release	NN	O
secretions	NNS	O
that	WDT	O
trigger	VBP	O
an	DT	O
inflammatory	JJ	O
response	NN	O
.	.	O
The	DT	O
classic	JJ	O
signs	NNS	O
of	IN	O
caldor	NN	O
,	,	O
rubor	NN	O
and	CC	O
dolor	NN	O
;	:	O
heat	NN	O
,	,	O
redness	NN	O
,	,	O
and	CC	O
pain	NN	O
characterize	JJ	O
inflammation	NN	O
.	.	O
White	NNP	O
blood	NN	O
cells	NNS	O
such	JJ	O
as	IN	O
macrophages	NNS	O
and	CC	O
neutrophils	NNS	O
migrate	VBP	O
from	IN	O
small	JJ	O
blood	NN	O
vessels	NNS	O
in	IN	O
the	DT	O
area	NN	O
to	TO	O
the	DT	O
infected	JJ	O
mucosa	NN	O
.	.	O
These	DT	O
cells	NNS	O
in	IN	O
turn	NN	O
release	NN	O
a	DT	O
variety	NN	O
of	IN	O
chemical	NN	O
mediators	NNS	O
that	WDT	O
increase	VBP	O
the	DT	O
inflammation	NN	O
.	.	O
Infectious	JJ	O
rhinitis	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
a	DT	O
purulent	NN	O
or	CC	O
pus	NN	O
like	IN	O
postnasal	NN	O
drip	NN	O
,	,	O
and	CC	O
nasal	JJ	O
congestion	NN	O
.	.	O
In	IN	O
many	JJ	O
viral	JJ	O
infections	NNS	O
there	EX	O
are	VBP	O
systemic	JJ	O
symptoms	NNS	O
such	JJ	O
as	IN	O
fever	NN	O
.	.	O
Treatment	NN	O
of	IN	O
viral	JJ	O
infection	NN	O
is	VBZ	O
symptomatic	JJ	O
with	IN	O
topical	JJ	O
and	CC	O
systemic	JJ	O
decongestants	NNS	O
,	,	O
and	CC	O
antipyretic	JJ	O
and	CC	O
anti-inflammatory	JJ	O
drugs	NNS	O
.	.	O
Vasomotor	NNP	O
and	CC	O
Other	JJ	O
Causes	NNP	O
of	IN	O
Rhinitis	NNP	O
Vasomotor	NNP	O
rhinitis	NN	O
is	VBZ	O
strictly	RB	O
a	DT	O
neural	JJ	O
hyper	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
serous	JJ	O
secretory	JJ	O
glands	NNS	O
of	IN	O
the	DT	O
nose	NN	O
.	.	O
This	DT	O
condition	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
a	DT	O
watery	NN	O
nasal	NN	O
discharge	NN	O
with	IN	O
a	DT	O
very	RB	O
small	JJ	O
content	NN	O
of	IN	O
mucus	NN	O
.	.	O
Vasomotor	NNP	O
rhinitis	NN	O
results	NNS	O
directly	RB	O
from	IN	O
neural	JJ	O
stimulation	NN	O
of	IN	O
temperature	NN	O
changes	NNS	O
or	CC	O
while	IN	O
eating	NN	O
,	,	O
and	CC	O
associated	VBD	O
other	JJ	O
symptoms	NNS	O
such	JJ	O
as	IN	O
congestion	NN	O
,	,	O
and	CC	O
sneezing	VBG	O
are	VBP	O
not	RB	O
prominent	JJ	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,766,605	CD	O
discloses	VBZ	O
a	DT	O
method	NN	O
of	IN	O
blocking	VBG	O
the	DT	O
symptom	NN	O
of	IN	O
rhinorrhea	NN	O
in	IN	O
vasomotor	NN	O
rhinitis	NN	O
using	VBG	O
clostridia	NN	O
neurotoxins	NNS	O
.	.	O
Serous	JJ	O
Otitis	NNP	O
Media	NNP	O
Direct	NNP	O
reaction	NN	O
of	IN	O
the	DT	O
middle	JJ	O
ear	NN	O
mucosa	NN	O
to	TO	O
allergens	VB	O
,	,	O
or	CC	O
indirect	JJ	O
effects	NNS	O
by	IN	O
blockage	NN	O
of	IN	O
the	DT	O
Eustachian	JJ	O
tube	NN	O
,	,	O
leads	VBZ	O
to	TO	O
serous	JJ	O
otitis	NN	O
media	NNS	O
.	.	O
In	IN	O
this	DT	O
condition	NN	O
the	DT	O
middle	JJ	O
ear	NN	O
fills	NNS	O
with	IN	O
fluid	NN	O
and	CC	O
hearing	NN	O
is	VBZ	O
impaired	VBN	O
.	.	O
As	IN	O
this	DT	O
condition	NN	O
most	RBS	O
often	RB	O
affects	VBZ	O
young	JJ	O
children	NNS	O
,	,	O
they	PRP	O
are	VBP	O
at	IN	O
risk	NN	O
of	IN	O
leaning	VBG	O
disabilities	NNS	O
due	JJ	O
to	TO	O
the	DT	O
decreased	VBN	O
hearing	NN	O
acuity	NN	O
.	.	O
Sinusitis	NN	O
,	,	O
a	DT	O
Complication	NN	O
of	IN	O
Rhinitis	NNP	O
Sinusitis	NNP	O
is	VBZ	O
an	DT	O
infection	NN	O
of	IN	O
the	DT	O
sinuses	NNS	O
.	.	O
The	DT	O
sinuses	NNS	O
are	VBP	O
air	NN	O
filled	VBN	O
cavities	NNS	O
surrounding	VBG	O
and	CC	O
opening	VBG	O
into	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
via	IN	O
small	JJ	O
openings	NNS	O
called	VBN	O
ostia	NN	O
.	.	O
The	DT	O
maxillary	JJ	O
sinuses	NNS	O
compose	VBP	O
the	DT	O
mass	NN	O
of	IN	O
the	DT	O
cheeks	NN	O
and	CC	O
the	DT	O
ostia	NN	O
are	VBP	O
between	IN	O
the	DT	O
inferior	JJ	O
and	CC	O
middle	JJ	O
turbinate	NN	O
.	.	O
The	DT	O
frontal	JJ	O
sinuses	NNS	O
are	VBP	O
above	IN	O
the	DT	O
brow	NN	O
underneath	IN	O
the	DT	O
skin	NN	O
of	IN	O
the	DT	O
forehead	NN	O
,	,	O
they	PRP	O
open	VBP	O
into	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
via	IN	O
a	DT	O
duct	NN	O
that	WDT	O
enters	VBZ	O
beneath	IN	O
the	DT	O
middle	JJ	O
turbinate	NN	O
.	.	O
The	DT	O
sphenoid	NN	O
sinuses	NNS	O
are	VBP	O
in	IN	O
the	DT	O
nasopharynx	NN	O
and	CC	O
have	VBP	O
ostia	VBN	O
on	IN	O
their	PRP$	O
anterior	JJ	O
surface	NN	O
.	.	O
The	DT	O
ethmoid	NN	O
sinuses	NNS	O
are	VBP	O
located	VBN	O
between	IN	O
the	DT	O
eyes	NNS	O
and	CC	O
are	VBP	O
composed	VBN	O
of	IN	O
numerous	JJ	O
small	JJ	O
air	NN	O
cells	NNS	O
.	.	O
The	DT	O
anterior	JJ	O
and	CC	O
posterior	JJ	O
cells	NNS	O
drain	VBP	O
independently	RB	O
.	.	O
The	DT	O
anterior	JJ	O
ethmoid	JJ	O
region	NN	O
is	VBZ	O
especially	RB	O
important	JJ	O
due	JJ	O
to	TO	O
the	DT	O
confluence	NN	O
of	IN	O
drainage	NN	O
ostia	NN	O
.	.	O
The	DT	O
area	NN	O
is	VBZ	O
called	VBN	O
the	DT	O
infundibulum	NN	O
,	,	O
and	CC	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
obstruction	NN	O
can	MD	O
cause	VB	O
widespread	JJ	O
sinus	NN	O
infections	NNS	O
.	.	O
Sinus	NNP	O
infections	NNS	O
are	VBP	O
either	DT	O
acute	NN	O
or	CC	O
chronic	NN	O
.	.	O
In	IN	O
acute	JJ	O
sinusitis	NN	O
a	DT	O
bacterial	JJ	O
infection	NN	O
follows	VBZ	O
a	DT	O
viral	JJ	O
infection	NN	O
of	IN	O
the	DT	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
.	.	O
However	RB	O
,	,	O
sinusitis	NN	O
can	MD	O
also	RB	O
occur	VB	O
from	IN	O
obstruction	NN	O
of	IN	O
the	DT	O
draining	VBG	O
ostia	NN	O
of	IN	O
the	DT	O
sinuses	NNS	O
by	IN	O
inflammation	NN	O
or	CC	O
mass	NN	O
lesion	NN	O
.	.	O
Topical	JJ	O
nasal	NN	O
decongestants	NNS	O
and	CC	O
systemic	JJ	O
antibiotics	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
treat	VB	O
acute	JJ	O
sinusitis	NN	O
.	.	O
Severe	NNP	O
or	CC	O
complicated	VBN	O
infections	NNS	O
may	MD	O
require	VB	O
surgical	JJ	O
drainage	NN	O
of	IN	O
the	DT	O
involved	JJ	O
sinus	NN	O
.	.	O
Chronic	NNP	O
sinusitis	NN	O
is	VBZ	O
a	DT	O
low-grade	JJ	O
ongoing	NN	O
or	CC	O
recurrent	JJ	O
infection	NN	O
of	IN	O
the	DT	O
sinuses	NNS	O
.	.	O
In	IN	O
these	DT	O
cases	NNS	O
the	DT	O
mucosa	NN	O
of	IN	O
the	DT	O
sinuses	NNS	O
has	VBZ	O
become	VBN	O
thickened	JJ	O
and	CC	O
enlarged	VBD	O
due	JJ	O
to	TO	O
edema	VB	O
and	CC	O
increased	JJ	O
secretory	NN	O
glandular	JJ	O
elements	NNS	O
.	.	O
In	IN	O
these	DT	O
cases	NNS	O
small	JJ	O
abscess	NN	O
may	MD	O
persist	VB	O
and	CC	O
relatively	RB	O
mild	JJ	O
inflammatory	JJ	O
stimuli	NNS	O
may	MD	O
cause	VB	O
obstruction	NN	O
of	IN	O
the	DT	O
narrowed	JJ	O
sinus	NN	O
ostia	NN	O
.	.	O
Treatment	NN	O
of	IN	O
chronic	JJ	O
sinusitis	NN	O
includes	VBZ	O
topical	JJ	O
steroid	NN	O
sprays	NNS	O
,	,	O
systemic	JJ	O
anti	NN	O
histamines	NNS	O
and	CC	O
decongestants	NNS	O
,	,	O
and/or	RB	O
surgical	JJ	O
removal	NN	O
of	IN	O
diseased	JJ	O
mucosa	NN	O
with	IN	O
enlargement	NN	O
of	IN	O
the	DT	O
ostia	NN	O
.	.	O
Asthma	NNP	O
Asthma	NNP	O
is	VBZ	O
a	DT	O
general	JJ	O
term	NN	O
given	VBN	O
to	TO	O
a	DT	O
similar	JJ	O
constellation	NN	O
of	IN	O
symptoms	NNS	O
:	:	O
bronchospasm	NN	O
,	,	O
mucosal	NN	O
swelling	VBG	O
and	CC	O
increased	JJ	O
secretions	NNS	O
.	.	O
Allergic	NNP	O
stimulation	NN	O
,	,	O
infections	NNS	O
,	,	O
irritating	VBG	O
chemicals	NNS	O
,	,	O
cold	JJ	O
air	NN	O
or	CC	O
exercise	NN	O
can	MD	O
trigger	VB	O
asthma	NN	O
.	.	O
Allergic	NNP	O
asthma	NN	O
is	VBZ	O
a	DT	O
specific	JJ	O
subset	NN	O
of	IN	O
asthma	NN	O
that	WDT	O
is	VBZ	O
initiated	VBN	O
by	IN	O
allergens	NNS	O
and	CC	O
involves	VBZ	O
the	DT	O
IgE	NNP	O
mediated	VBD	O
reaction	NN	O
.	.	O
Local	JJ	O
and	CC	O
organ	JJ	O
reactions	NNS	O
include	VBP	O
bronchial	JJ	O
smooth	JJ	O
muscle	NN	O
constriction	NN	O
,	,	O
mucosal	NN	O
swelling	VBG	O
and	CC	O
increased	JJ	O
secretions	NNS	O
.	.	O
Other	JJ	O
Allergic	NNP	O
Conditions	NNP	O
Other	JJ	O
allergic	JJ	O
conditions	NNS	O
include	VBP	O
food	NN	O
allergies	NNS	O
,	,	O
and	CC	O
allergic	JJ	O
dermatitis	NN	O
.	.	O
Clostridia	NNP	O
Neurotoxins	NNP	O
(	(	O
CnT	NNP	O
)	)	O
Clostridium	NNP	O
(	(	O
C.	NNP	O
)	)	O
botulinum	NN	O
and	CC	O
the	DT	O
closely	RB	O
related	JJ	O
species	NNS	O
C.	NNP	O
butyricum	NN	O
and	CC	O
beratti	NN	O
produce	VBP	O
an	DT	O
extremely	RB	O
powerful	JJ	O
neurotoxin	NN	O
that	WDT	O
causes	VBZ	O
the	DT	O
paralytic	JJ	O
condition	NN	O
known	VBN	O
as	IN	O
botulism	NN	O
.	.	O
The	DT	O
botulinum	NN	O
neurotoxin	NN	O
(	(	O
BoNT	NNP	O
)	)	O
protein	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
light	NN	O
and	CC	O
heavy	JJ	O
chain	NN	O
that	IN	O
together	RB	O
weigh	JJ	O
approximately	RB	O
150	CD	O
kD	NNS	O
.	.	O
In	IN	O
botulism	NN	O
the	DT	O
primary	JJ	O
target	NN	O
is	VBZ	O
the	DT	O
synapse	NN	O
of	IN	O
the	DT	O
motor	NN	O
neuron	NN	O
with	IN	O
the	DT	O
muscle	NN	O
fiber	NN	O
.	.	O
Here	RB	O
BoNT	NNP	O
is	VBZ	O
taken	VBN	O
up	RP	O
by	IN	O
the	DT	O
membrane	NN	O
of	IN	O
the	DT	O
motor	NN	O
neuron	NN	O
and	CC	O
is	VBZ	O
internalized	VBN	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
to	TO	O
inhibit	VB	O
the	DT	O
release	NN	O
of	IN	O
neurotransmitters	NNS	O
and	CC	O
neuropeptides	NNS	O
by	IN	O
neurons	NNS	O
.	.	O
In	IN	O
clinical	JJ	O
use	NN	O
each	DT	O
serotype	NN	O
appears	VBZ	O
to	TO	O
differ	VB	O
in	IN	O
its	PRP$	O
potency	NN	O
in	IN	O
blocking	VBG	O
different	JJ	O
classes	NNS	O
of	IN	O
neurons	NNS	O
.	.	O
BoNT	NNP	O
works	NNS	O
by	IN	O
a	DT	O
two-stage	NN	O
mechanism	NN	O
,	,	O
uptake	JJ	O
and	CC	O
molecular	JJ	O
action	NN	O
.	.	O
Peripheral	NNP	O
nerve	NN	O
terminals	NNS	O
take	VBP	O
up	RP	O
BoNT	NNP	O
.	.	O
After	IN	O
translocation	NN	O
across	IN	O
the	DT	O
cell	NN	O
membrane	NN	O
BoNT	NNP	O
interferes	VBZ	O
with	IN	O
the	DT	O
molecular	JJ	O
mechanism	NN	O
of	IN	O
neurosecretion	NN	O
.	.	O
Specifically	RB	O
,	,	O
BoNT	NNP	O
cleaves	VBZ	O
the	DT	O
proteins	NNS	O
involved	VBN	O
in	IN	O
synaptic	JJ	O
vesicle	NN	O
docking	NN	O
and	CC	O
release	NN	O
called	VBD	O
the	DT	O
SNARE	NNP	O
complex	NN	O
.	.	O
The	DT	O
result	NN	O
is	VBZ	O
to	TO	O
block	VB	O
neural	JJ	O
signals	NNS	O
.	.	O
C.	NNP	O
tetani	NN	O
produce	VBP	O
tetanus	NN	O
neurotoxin	NN	O
(	(	O
TeNT	NNP	O
)	)	O
.	.	O
TeNT	NNP	O
is	VBZ	O
similar	JJ	O
to	TO	O
the	DT	O
BoNTs	NNP	O
in	IN	O
that	IN	O
it	PRP	O
interferes	VBZ	O
with	IN	O
vesicle	NN	O
release	NN	O
by	IN	O
cleaving	VBG	O
VAMP	NNP	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
SNARE	NNP	O
family	NN	O
of	IN	O
proteins	NNS	O
.	.	O
However	RB	O
the	DT	O
in	IN	O
vivo	JJ	O
biological	JJ	O
activity	NN	O
of	IN	O
TeNT	NNP	O
is	VBZ	O
usually	RB	O
quite	RB	O
different	JJ	O
from	IN	O
BoNT	NNP	O
.	.	O
The	DT	O
systemic	JJ	O
disorder	NN	O
tetanus	NN	O
results	NNS	O
from	IN	O
TeNT	NNP	O
produced	VBD	O
at	IN	O
a	DT	O
wound	NN	O
site	NN	O
and	CC	O
disseminated	VBN	O
throughout	IN	O
the	DT	O
body	NN	O
via	IN	O
the	DT	O
blood	NN	O
stream	NN	O
.	.	O
The	DT	O
TeNT	NNP	O
is	VBZ	O
taken	VBN	O
up	RP	O
by	IN	O
peripheral	JJ	O
motor	NN	O
neurons	NNS	O
and	CC	O
transported	VBN	O
to	TO	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
.	.	O
The	DT	O
TeNT	NNP	O
then	RB	O
preferentially	RB	O
blocks	VBZ	O
inhibitory	JJ	O
neurons	NNS	O
connecting	VBG	O
to	TO	O
the	DT	O
motor	NN	O
neuron	NN	O
,	,	O
thereby	RB	O
allowing	VBG	O
unopposed	JJ	O
excitatory	NN	O
input	NN	O
.	.	O
However	RB	O
,	,	O
at	IN	O
higher	JJR	O
doses	NNS	O
TeNT	NNP	O
and	CC	O
when	WRB	O
introduced	VBN	O
directly	RB	O
into	IN	O
the	DT	O
neuron	NN	O
also	RB	O
blocks	VBZ	O
all	DT	O
neurons	NNS	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
as	IN	O
BoNT	NNP	O
.	.	O
In	IN	O
this	DT	O
application	NN	O
it	PRP	O
is	VBZ	O
assumed	VBN	O
that	IN	O
when	WRB	O
BoNT	NNP	O
is	VBZ	O
discussed	VBN	O
,	,	O
is	VBZ	O
includes	VBZ	O
the	DT	O
TeNT	NNP	O
when	WRB	O
used	VBN	O
at	IN	O
higher	JJR	O
blocking	NN	O
doses	NNS	O
.	.	O
At	IN	O
present	JJ	O
seven	CD	O
immunologically	RB	O
distinct	JJ	O
serotypes	NNS	O
of	IN	O
the	DT	O
BoNT	NNP	O
are	VBP	O
known	VBN	O
,	,	O
named	VBN	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
,	,	O
F	NNP	O
and	CC	O
G.	NNP	O
The	DT	O
type	NN	O
C	NNP	O
serotype	NN	O
is	VBZ	O
now	RB	O
known	VBN	O
to	TO	O
be	VB	O
divided	VBN	O
into	IN	O
three	CD	O
different	JJ	O
toxins	NNS	O
with	IN	O
distinct	JJ	O
biological	JJ	O
effects	NNS	O
.	.	O
Only	RB	O
C1	NNP	O
is	VBZ	O
a	DT	O
neurotoxin	NN	O
,	,	O
whereas	JJ	O
C2	NNP	O
and	CC	O
C3	NNP	O
are	VBP	O
not	RB	O
.	.	O
C2	NNP	O
is	VBZ	O
distinctive	JJ	O
for	IN	O
blocking	VBG	O
actin	JJ	O
formation	NN	O
,	,	O
which	WDT	O
can	MD	O
prevent	VB	O
mast	NN	O
cell	NN	O
degranulation	NN	O
.	.	O
Although	IN	O
all	DT	O
BoNT	NNP	O
serotypes	NNS	O
interfere	RB	O
with	IN	O
proteins	NNS	O
that	WDT	O
cause	VBP	O
the	DT	O
release	NN	O
of	IN	O
synaptic	JJ	O
vesicles	NNS	O
from	IN	O
cells	NNS	O
they	PRP	O
each	DT	O
interfere	VBP	O
with	IN	O
different	JJ	O
proteins	NNS	O
,	,	O
or	CC	O
different	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
same	JJ	O
protein	NN	O
:	:	O
Most	JJS	O
if	IN	O
not	RB	O
all	DT	O
cell	NN	O
types	NNS	O
use	VBP	O
the	DT	O
vesicle	NN	O
system	NN	O
for	IN	O
secretion	NN	O
,	,	O
although	IN	O
the	DT	O
molecules	NNS	O
within	IN	O
these	DT	O
vesicles	NNS	O
differ	VBP	O
for	IN	O
each	DT	O
type	NN	O
of	IN	O
cell	NN	O
.	.	O
If	IN	O
experimentally	RB	O
introduced	VBN	O
into	IN	O
any	DT	O
cell	NN	O
BoNT	NNP	O
appears	VBZ	O
capable	JJ	O
of	IN	O
blocking	VBG	O
its	PRP$	O
vesicle	NN	O
release	NN	O
.	.	O
However	RB	O
,	,	O
in	IN	O
nature	NN	O
BoNT	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
internalized	VBN	O
into	IN	O
neurons	NNS	O
,	,	O
particularly	RB	O
the	DT	O
efferent	NN	O
neurons	NNS	O
.	.	O
The	DT	O
vesicles	NNS	O
within	IN	O
neurons	NNS	O
contain	VBP	O
classical	JJ	O
neurotransmitters	NNS	O
(	(	O
acetylcholine	NN	O
,	,	O
epinephrine	NN	O
,	,	O
nor	CC	O
epinephrine	NN	O
,	,	O
dopamine	NN	O
,	,	O
serotonin	NN	O
,	,	O
glutamate	NN	O
,	,	O
GABA	NNP	O
and	CC	O
others	NNS	O
)	)	O
and/or	VBP	O
neuropeptides	NNS	O
(	(	O
substance	NN	O
P	NNP	O
,	,	O
neurokinin	VBZ	O
A	NNP	O
,	,	O
calcitonin	NN	O
gene	NN	O
related	VBN	O
peptide	RB	O
(	(	O
CGRP	NNP	O
)	)	O
,	,	O
neuropeptide	RB	O
Y	NNP	O
,	,	O
interleukins	VBZ	O
,	,	O
growth	NN	O
factors	NNS	O
and	CC	O
others	NNS	O
)	)	O
.	.	O
Although	IN	O
the	DT	O
highest	JJS	O
affinity	NN	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
for	IN	O
cholinergic	JJ	O
neurons	NNS	O
,	,	O
in	IN	O
various	JJ	O
preparations	NNS	O
BoNT	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
block	VB	O
secretion	NN	O
of	IN	O
all	PDT	O
these	DT	O
molecules	NNS	O
.	.	O
The	DT	O
Clinical	JJ	O
Effects	NNS	O
of	IN	O
Botulinum	NNP	O
Toxin	NNP	O
on	IN	O
Different	NNP	O
Classes	NNP	O
of	IN	O
Neurons	NNP	O
Voluntary	NNP	O
Motor	NNP	O
Nerves	VBZ	O
The	DT	O
first	JJ	O
and	CC	O
still	RB	O
primary	JJ	O
use	NN	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
to	TO	O
block	VB	O
motor	NN	O
nerve	NN	O
communication	NN	O
with	IN	O
muscle	NN	O
fibers	NNS	O
.	.	O
BoNT	NNP	O
is	VBZ	O
injected	VBN	O
within	IN	O
the	DT	O
target	NN	O
muscle	NN	O
.	.	O
The	DT	O
BoNT	NNP	O
is	VBZ	O
then	RB	O
internalized	VBN	O
into	IN	O
motor	NN	O
neurons	NNS	O
where	WRB	O
it	PRP	O
decreases	VBZ	O
or	CC	O
stops	VBZ	O
the	DT	O
release	NN	O
of	IN	O
the	DT	O
neurotransmitter	NN	O
acetylcholine	NN	O
(	(	O
AChE	NNP	O
)	)	O
,	,	O
thereby	RB	O
causing	VBG	O
paresis	NN	O
or	CC	O
paralysis	NN	O
of	IN	O
the	DT	O
muscle	NN	O
.	.	O
Scott	NNP	O
introduced	VBD	O
the	DT	O
concept	NN	O
of	IN	O
localized	JJ	O
muscular	JJ	O
injections	NNS	O
of	IN	O
BoNT	NNP	O
in	IN	O
the	DT	O
specific	JJ	O
condition	NN	O
of	IN	O
strabismus	NN	O
(	(	O
squint	NN	O
,	,	O
crossed	JJ	O
eyes	NNS	O
)	)	O
.	.	O
Later	RB	O
BoNT	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
particularly	RB	O
useful	JJ	O
for	IN	O
movement	NN	O
disorders	NNS	O
such	JJ	O
as	IN	O
tics	NNS	O
,	,	O
spasms	NNS	O
,	,	O
contractures	NNS	O
,	,	O
cramps	NNS	O
and	CC	O
tremors	NNS	O
.	.	O
More	RBR	O
recently	RB	O
,	,	O
the	DT	O
injection	NN	O
of	IN	O
BoNT	NNP	O
into	IN	O
facial	JJ	O
muscles	NNS	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
ameliorate	VB	O
skin	NN	O
wrinkling	NN	O
and	CC	O
lines	NNS	O
related	VBN	O
to	TO	O
aging	VBG	O
.	.	O
Another	DT	O
recent	JJ	O
application	NN	O
of	IN	O
BoNT	NNP	O
injections	NNS	O
is	VBZ	O
to	TO	O
decrease	VB	O
the	DT	O
pain	NN	O
accompanying	VBG	O
muscle	NN	O
tension	NN	O
in	IN	O
conditions	NNS	O
such	JJ	O
as	IN	O
headache	NN	O
and	CC	O
temporo-mandibular	JJ	O
joint	JJ	O
syndrome	NN	O
.	.	O
Autonomic	NNP	O
Motor	NNP	O
Neurons	NNP	O
Effector	NNP	O
neurons	NNS	O
of	IN	O
the	DT	O
autonomic	JJ	O
system	NN	O
innervate	NN	O
and	CC	O
control	VB	O
the	DT	O
contraction	NN	O
of	IN	O
smooth	JJ	O
muscles	NNS	O
using	VBG	O
AChE	NNP	O
as	IN	O
the	DT	O
neurotransmitter	NN	O
.	.	O
Injections	NNS	O
of	IN	O
BoNT	NNP	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
decrease	VB	O
tone	NN	O
in	IN	O
the	DT	O
smooth	JJ	O
muscles	NNS	O
of	IN	O
the	DT	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
,	,	O
esophagus	NN	O
,	,	O
stomach	NN	O
wall	NN	O
,	,	O
and	CC	O
pyloric	JJ	O
sphincter	NN	O
,	,	O
sphincter	NN	O
of	IN	O
Odi	NNP	O
,	,	O
anal	JJ	O
sphincter	NN	O
,	,	O
and	CC	O
urinary	JJ	O
bladder	NN	O
.	.	O
Autonomic	NNP	O
Secretory	NNP	O
Neurons	NNP	O
Effector	NNP	O
neurons	NNS	O
of	IN	O
the	DT	O
autonomic	JJ	O
system	NN	O
control	NN	O
or	CC	O
modulate	VB	O
the	DT	O
secretion	NN	O
of	IN	O
various	JJ	O
water	NN	O
and	CC	O
mucoid	NN	O
fluids	NNS	O
throughout	IN	O
the	DT	O
body	NN	O
.	.	O
BoNT	NNP	O
injections	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
decrease	VB	O
sweating	NN	O
,	,	O
salivary	JJ	O
gland	NN	O
flow	NN	O
,	,	O
gastric	JJ	O
secretions	NNS	O
including	VBG	O
acid	JJ	O
production	NN	O
,	,	O
nasal	NN	O
and	CC	O
other	JJ	O
respiratory	NN	O
secretions	NNS	O
,	,	O
and	CC	O
tearing	NN	O
.	.	O
Sensory	JJ	O
Neurons	NNP	O
Sensory	NNP	O
neurons	NNS	O
release	VBP	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
neuropeptides	NNS	O
,	,	O
cytokines	NNS	O
,	,	O
growth	NN	O
factors	NNS	O
and	CC	O
other	JJ	O
substances	NNS	O
that	WDT	O
effect	NN	O
parenchymal	NN	O
cells	NNS	O
,	,	O
blood	NN	O
vessels	NNS	O
and	CC	O
immune	JJ	O
cells	NNS	O
.	.	O
Notable	JJ	O
is	VBZ	O
that	IN	O
these	DT	O
substances	NNS	O
can	MD	O
activate	VB	O
mast	NN	O
cells	NNS	O
directly	RB	O
thereby	RB	O
extending	VBG	O
the	DT	O
allergic	JJ	O
reaction	NN	O
.	.	O
Except	IN	O
for	IN	O
nitrous	JJ	O
oxide	IN	O
these	DT	O
substances	NNS	O
are	VBP	O
released	VBN	O
via	IN	O
the	DT	O
SNARE	NNP	O
mechanism	NN	O
and	CC	O
can	MD	O
be	VB	O
blocked	VBN	O
by	IN	O
CnT	NNP	O
.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
As	IN	O
used	VBN	O
herein	NN	O
‘	NNP	O
local	JJ	O
administration	NN	O
’	NNP	O
includes	VBZ	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
injection	NN	O
by	IN	O
needle	JJ	O
and	CC	O
in-dwelling	JJ	O
catheter	NN	O
(	(	O
including	VBG	O
pressure	NN	O
jet	NN	O
injectors	NNS	O
)	)	O
,	,	O
topical	JJ	O
administration	NN	O
in	IN	O
lyophilized	JJ	O
powder	NN	O
,	,	O
liquid	JJ	O
solutions	NNS	O
,	,	O
creams	NNS	O
,	,	O
ointments	NNS	O
,	,	O
aerosolized	VBD	O
or	CC	O
introduced	VBN	O
by	IN	O
liposomal	JJ	O
(	(	O
niosomes	NNS	O
)	)	O
vectors	NNS	O
,	,	O
or	CC	O
as	IN	O
nucleic	JJ	O
acid	NN	O
introduced	VBN	O
by	IN	O
viral	JJ	O
or	CC	O
other	JJ	O
vectors	NNS	O
.	.	O
The	DT	O
CnT	NNP	O
may	MD	O
also	RB	O
be	VB	O
embedded	VBN	O
in	IN	O
biopolymers	NNS	O
or	CC	O
delivered	VBN	O
by	IN	O
implanted	JJ	O
pumps	NNS	O
to	TO	O
release	VB	O
the	DT	O
CnT	NNP	O
into	IN	O
solution	NN	O
over	IN	O
prolonged	JJ	O
periods	NNS	O
.	.	O
By	IN	O
“	NNP	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
”	NN	O
it	PRP	O
is	VBZ	O
meant	VBN	O
of	IN	O
purposes	NNS	O
of	IN	O
this	DT	O
invention	NN	O
that	IN	O
the	DT	O
CnT	NNP	O
is	VBZ	O
administered	VBN	O
in	IN	O
a	DT	O
non-toxic	JJ	O
amount	NN	O
sufficient	NN	O
to	TO	O
cause	VB	O
reduction	NN	O
in	IN	O
the	DT	O
occurrence	NN	O
or	CC	O
magnitude	NN	O
of	IN	O
the	DT	O
symptoms	NNS	O
being	VBG	O
targeted	VBN	O
.	.	O
By	IN	O
“	NNP	O
unit	NN	O
”	NN	O
it	PRP	O
is	VBZ	O
meant	VBN	O
the	DT	O
biological	JJ	O
equivalent	NN	O
of	IN	O
the	DT	O
current	JJ	O
unit	NN	O
measure	NN	O
used	VBN	O
for	IN	O
botulinum	NN	O
toxin	NN	O
A	NNP	O
marketed	VBD	O
as	IN	O
Botox	NNP	O
.	.	O
At	IN	O
present	JJ	O
BoNT	NNP	O
is	VBZ	O
measured	VBN	O
by	IN	O
biological	JJ	O
assay	NN	O
;	:	O
a	DT	O
unit	NN	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
the	DT	O
amount	NN	O
that	WDT	O
causes	VBZ	O
death	NN	O
to	TO	O
50	CD	O
%	NN	O
of	IN	O
mice	NN	O
when	WRB	O
injected	VBN	O
intraperitoneally	RB	O
.	.	O
BoNT-A	NNP	O
is	VBZ	O
marketed	VBN	O
as	IN	O
Botox	NNP	O
by	IN	O
Allergan	NNP	O
Corp	NNP	O
,	,	O
Irvine	NNP	O
Ca	NNP	O
,	,	O
and	CC	O
as	IN	O
Dysport	NNP	O
by	IN	O
Ipsen	NNP	O
Ltd	NNP	O
,	,	O
Berks	NNP	O
United	NNP	O
Kingdom	NNP	O
.	.	O
Although	IN	O
the	DT	O
biological	JJ	O
assay	NN	O
is	VBZ	O
done	VBN	O
the	DT	O
same	JJ	O
way	NN	O
the	DT	O
in	IN	O
vivo	JJ	O
effect	NN	O
of	IN	O
Botox	NNP	O
and	CC	O
Dysport	NNP	O
vary	VBP	O
.	.	O
BoNT-B	NNP	O
is	VBZ	O
marketed	VBN	O
as	IN	O
Myobloc	NNP	O
by	IN	O
Elan	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Dublin	NNP	O
,	,	O
Ireland	NNP	O
.	.	O
TeNT	NNP	O
is	VBZ	O
not	RB	O
commercially	RB	O
available	JJ	O
but	CC	O
other	JJ	O
assays	NNS	O
have	VBP	O
compared	VBN	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
blocking	VBG	O
effect	NN	O
of	IN	O
TeNT	NNP	O
to	TO	O
BoNT	NNP	O
.	.	O
All	DT	O
serotypes	NNS	O
of	IN	O
BoNT	NNP	O
as	RB	O
well	RB	O
as	IN	O
TeNT	NNP	O
are	VBP	O
commercially	RB	O
available	JJ	O
from	IN	O
List	NNP	O
Biological	NNP	O
Laboratories	NNPS	O
.	.	O
A	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
BoNT	NNP	O
will	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
organ	NN	O
to	TO	O
be	VB	O
treated	VBN	O
,	,	O
how	WRB	O
much	JJ	O
of	IN	O
the	DT	O
organ	NN	O
will	MD	O
be	VB	O
treated	VBN	O
,	,	O
the	DT	O
method	NN	O
of	IN	O
application	NN	O
and	CC	O
the	DT	O
exact	JJ	O
preparation	NN	O
of	IN	O
BoNT	NNP	O
used	VBD	O
.	.	O
A	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
will	MD	O
vary	VB	O
from	IN	O
a	DT	O
fraction	NN	O
of	IN	O
a	DT	O
unit	NN	O
to	TO	O
hundreds	NNS	O
of	IN	O
units	NNS	O
as	IN	O
it	PRP	O
currently	RB	O
does	VBZ	O
with	IN	O
intramuscular	JJ	O
injections	NNS	O
.	.	O
The	DT	O
exact	JJ	O
dosage	NN	O
will	MD	O
not	RB	O
require	VB	O
undo	JJ	O
experimentation	NN	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Where	WRB	O
solutions	NNS	O
or	CC	O
suspensions	NNS	O
of	IN	O
BoNT	NNP	O
or	CC	O
CnT	NNP	O
are	VBP	O
referred	VBN	O
to	TO	O
,	,	O
unless	IN	O
indicated	VBN	O
to	TO	O
the	DT	O
contrary	JJ	O
,	,	O
this	DT	O
means	VBZ	O
the	DT	O
designated	JJ	O
number	NN	O
of	IN	O
units	NNS	O
in	IN	O
1	CD	O
ml	NN	O
of	IN	O
Normal	NNP	O
saline	NN	O
.	.	O
By	IN	O
“	NNP	O
CnT	NNP	O
”	IN	O
it	PRP	O
is	VBZ	O
meant	JJ	O
that	IN	O
any	DT	O
biological	JJ	O
substance	NN	O
having	VBG	O
essentially	RB	O
the	DT	O
same	JJ	O
biological	JJ	O
effect	NN	O
within	IN	O
cells	NNS	O
as	IN	O
the	DT	O
wild	JJ	O
types	NNS	O
of	IN	O
clostridia	NN	O
neurotoxins	NNS	O
.	.	O
Specifically	RB	O
,	,	O
to	TO	O
block	VB	O
or	CC	O
decrease	VB	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
SNARE	NNP	O
family	NN	O
of	IN	O
proteins	NNS	O
involved	VBN	O
in	IN	O
secretion	NN	O
of	IN	O
allergy	NN	O
related	VBN	O
neurohumors	NNS	O
.	.	O
Numerous	JJ	O
substitutions	NNS	O
for	IN	O
the	DT	O
major	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
CnT	NNP	O
have	VBP	O
been	VBN	O
disclosed	VBN	O
and	CC	O
these	DT	O
are	VBP	O
all	DT	O
included	VBN	O
in	IN	O
this	DT	O
specification	NN	O
.	.	O
This	DT	O
would	MD	O
include	VB	O
fragments	NNS	O
,	,	O
altered	VBD	O
forms	NNS	O
,	,	O
and	CC	O
recombinant	JJ	O
forms	NNS	O
of	IN	O
CnT	NNP	O
.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
chimeras	NNS	O
,	,	O
hybrids	NNS	O
and	CC	O
conjugates	NNS	O
.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
the	DT	O
use	NN	O
of	IN	O
DNA	NNP	O
and	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
are	VBP	O
directly	RB	O
applied	VBN	O
and	CC	O
translated	VBN	O
in	IN	O
the	DT	O
allergic	JJ	O
sites	NNS	O
.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
“	JJ	O
vectors	NNS	O
”	VBP	O
,	,	O
various	JJ	O
compositions	NNS	O
that	WDT	O
deliver	VBP	O
a	DT	O
botulinum	NN	O
or	CC	O
tetanus	NN	O
toxin	NN	O
light	NN	O
chain	NN	O
or	CC	O
its	PRP$	O
equivalent	JJ	O
such	JJ	O
as	IN	O
Protease	NNP	O
A	NNP	O
across	NN	O
cell	NN	O
membranes	NNS	O
.	.	O
These	DT	O
vectors	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
viruses	NNS	O
,	,	O
liposomes	NNS	O
,	,	O
noisomes	NNS	O
,	,	O
and	CC	O
protein	JJ	O
transduction	NN	O
domains	NNS	O
(	(	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Application	NNP	O
60/449,107	CD	O
)	)	O
.	.	O
Allergic	NNP	O
“	NNP	O
neurohumors	NNS	O
”	VBP	O
are	VBP	O
neurotransmitters	NNS	O
,	,	O
neuropeptides	NNS	O
and	CC	O
cytokines	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
allergic	JJ	O
reactions	NNS	O
and	CC	O
whose	WP$	O
secretion	NN	O
or	CC	O
action	NN	O
can	MD	O
be	VB	O
blocked	VBN	O
by	IN	O
CnT	NNP	O
.	.	O
They	PRP	O
include	VBP	O
acetylcholine	JJ	O
,	,	O
noradrenaline	JJ	O
,	,	O
neuropeptide	JJ	O
Y	NNP	O
,	,	O
substance	NN	O
P	NNP	O
,	,	O
calcitonin	NN	O
gene	NN	O
reactive	JJ	O
protein	NN	O
(	(	O
CGRP	NNP	O
)	)	O
,	,	O
histamine	NN	O
,	,	O
nerve	NN	O
growth	NN	O
factor	NN	O
,	,	O
and	CC	O
interleukins	NNS	O
.	.	O
The	DT	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
blocking	VBG	O
or	CC	O
reducing	VBG	O
physiological	JJ	O
reaction	NN	O
in	IN	O
a	DT	O
mammal	NN	O
,	,	O
suitably	RB	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
H.	NNP	O
sapiens	NNS	O
,	,	O
to	TO	O
the	DT	O
interaction	NN	O
of	IN	O
IgE	NNP	O
antibodies	NNS	O
present	VBP	O
in	IN	O
said	VBD	O
mammal	JJ	O
upon	IN	O
contact	NN	O
with	IN	O
the	DT	O
corresponding	JJ	O
antigen	NN	O
.	.	O
This	DT	O
blocking	NN	O
is	VBZ	O
achieved	VBN	O
by	IN	O
the	DT	O
administration	NN	O
to	TO	O
said	VBD	O
mammal	NN	O
of	IN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
neurotoxin	NN	O
(	(	O
CnT	NNP	O
)	)	O
derived	VBD	O
from	IN	O
Clostridia	NNP	O
sp	NN	O
.	.	O
Suitably	RB	O
,	,	O
the	DT	O
CnT	NNP	O
is	VBZ	O
derived	VBN	O
from	IN	O
a	DT	O
species	NNS	O
of	IN	O
Clostridia	NNP	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
C.	NNP	O
botulinum	NN	O
,	,	O
C.	NNP	O
butyricum	NN	O
,	,	O
C.	NNP	O
beratti	NN	O
,	,	O
C.	NNP	O
tetani	NN	O
.	.	O
The	DT	O
neurotoxins	NNS	O
(	(	O
BoNT	NNP	O
)	)	O
,	,	O
derived	VBN	O
from	IN	O
C.	NNP	O
botulinum	NN	O
,	,	O
are	VBP	O
derived	VBN	O
from	IN	O
serotypes	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C1	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
,	,	O
F	NNP	O
and	CC	O
G	NNP	O
,	,	O
while	IN	O
neurotoxin	NN	O
(	(	O
TeNT	NNP	O
)	)	O
,	,	O
is	VBZ	O
derived	VBN	O
from	IN	O
C.	NNP	O
tetani	NN	O
BoNT/A	NNP	O
is	VBZ	O
marketed	VBN	O
as	IN	O
Botox®	NNP	O
by	IN	O
Allergan	NNP	O
Inc	NNP	O
and	CC	O
as	IN	O
Dysport®	NNP	O
by	IN	O
Ipsen	NNP	O
Ltd	NNP	O
as	IN	O
a	DT	O
lyophilized	JJ	O
powder	NN	O
that	WDT	O
is	VBZ	O
reconstituted	VBN	O
with	IN	O
preservative	JJ	O
free	JJ	O
normal	JJ	O
saline	NN	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O
BoNT/B	NNP	O
is	VBZ	O
marketed	VBN	O
as	IN	O
Myobloc®	NNP	O
by	IN	O
Elan	NNP	O
Pharmaceuticals	NNP	O
in	IN	O
normal	JJ	O
saline	JJ	O
solution	NN	O
.	.	O
The	DT	O
light	NN	O
chains	NNS	O
and	CC	O
holotoxins	NNS	O
for	IN	O
each	DT	O
BoNT	NNP	O
serotypes	NNS	O
and	CC	O
TeNT	NNP	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
List	NNP	O
Biological	NNP	O
Labs	NNP	O
and/or	IN	O
Metabiologics	NNP	O
Inc.	NNP	O
CnT	NNP	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
inventions	NNS	O
are	VBP	O
prepared	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
forms	NNS	O
depending	VBG	O
on	IN	O
whether	IN	O
the	DT	O
composition	NN	O
is	VBZ	O
injected	VBN	O
or	CC	O
implanted	VBN	O
,	,	O
topically	RB	O
applied	VBN	O
to	TO	O
respiratory	VB	O
mucosa	NN	O
of	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
or	CC	O
lungs	NNS	O
,	,	O
gastrointestinal	JJ	O
mucosa	NN	O
,	,	O
or	CC	O
to	TO	O
skin	VB	O
.	.	O
For	IN	O
all	DT	O
injectable	JJ	O
CnT	NNP	O
compositions	NNS	O
fluid	VBP	O
dosage	NN	O
forms	NNS	O
are	VBP	O
prepared	JJ	O
utilizing	VBG	O
the	DT	O
compound	NN	O
and	CC	O
a	DT	O
pyrogen-free	JJ	O
sterile	JJ	O
vehicle	NN	O
.	.	O
The	DT	O
compound	NN	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
vehicle	NN	O
and	CC	O
concentration	NN	O
used	VBN	O
,	,	O
can	MD	O
be	VB	O
either	RB	O
dissolved	VBN	O
or	CC	O
suspended	VBN	O
in	IN	O
the	DT	O
vehicle	NN	O
.	.	O
In	IN	O
preparing	VBG	O
solutions	NNS	O
the	DT	O
compound	NN	O
can	MD	O
be	VB	O
dissolved	VBN	O
in	IN	O
the	DT	O
vehicle	NN	O
,	,	O
the	DT	O
solution	NN	O
being	VBG	O
made	VBN	O
isotonic	JJ	O
if	IN	O
necessary	JJ	O
by	IN	O
addition	NN	O
of	IN	O
sodium	NN	O
chloride	NN	O
and	CC	O
sterilized	VBN	O
by	IN	O
filtration	NN	O
through	IN	O
a	DT	O
sterile	JJ	O
filter	NN	O
using	VBG	O
aseptic	JJ	O
techniques	NNS	O
before	IN	O
filling	VBG	O
into	IN	O
suitable	JJ	O
sterile	JJ	O
vials	NNS	O
or	CC	O
ampoules	NNS	O
and	CC	O
sealing	NN	O
.	.	O
Alternatively	RB	O
,	,	O
if	IN	O
solution	NN	O
stability	NN	O
is	VBZ	O
adequate	JJ	O
,	,	O
the	DT	O
solution	NN	O
in	IN	O
its	PRP$	O
sealed	JJ	O
containers	NNS	O
may	MD	O
be	VB	O
sterilized	VBN	O
by	IN	O
autoclaving	VBG	O
.	.	O
Advantageously	RB	O
additives	NNS	O
such	JJ	O
as	IN	O
buffering	NN	O
,	,	O
solubilizing	VBG	O
,	,	O
stabilizing	VBG	O
,	,	O
preservative	JJ	O
or	CC	O
bactericidal	JJ	O
,	,	O
suspending	VBG	O
or	CC	O
emulsifying	VBG	O
agents	NNS	O
and/or	JJ	O
local	JJ	O
anaesthetic	JJ	O
agents	NNS	O
may	MD	O
be	VB	O
dissolved	VBN	O
in	IN	O
the	DT	O
vehicle	NN	O
.	.	O
Dry	NNP	O
powders	NNS	O
,	,	O
which	WDT	O
are	VBP	O
dissolved	VBN	O
or	CC	O
suspended	VBN	O
in	IN	O
a	DT	O
suitable	JJ	O
vehicle	NN	O
prior	RB	O
to	TO	O
use	VB	O
,	,	O
may	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
filling	VBG	O
pre-sterilized	JJ	O
drug	NN	O
substance	NN	O
and	CC	O
other	JJ	O
ingredients	NNS	O
into	IN	O
a	DT	O
sterile	JJ	O
container	NN	O
using	VBG	O
aseptic	JJ	O
technique	NN	O
in	IN	O
a	DT	O
sterile	JJ	O
area	NN	O
.	.	O
Alternatively	RB	O
the	DT	O
drug	NN	O
and	CC	O
other	JJ	O
ingredients	NNS	O
may	MD	O
be	VB	O
dissolved	VBN	O
into	IN	O
suitable	JJ	O
containers	NNS	O
using	VBG	O
aseptic	JJ	O
technique	NN	O
in	IN	O
a	DT	O
sterile	JJ	O
area	NN	O
.	.	O
The	DT	O
product	NN	O
is	VBZ	O
then	RB	O
freeze-dried	JJ	O
and	CC	O
the	DT	O
containers	NNS	O
are	VBP	O
sealed	VBN	O
aseptically	RB	O
.	.	O
In	IN	O
the	DT	O
respiratory	NN	O
and	CC	O
gastrointestinal	JJ	O
systems	NNS	O
,	,	O
CnT	NNP	O
binds	VBZ	O
to	TO	O
mucosal	VB	O
epithelial	JJ	O
cells	NNS	O
and	CC	O
is	VBZ	O
actively	RB	O
transcytosed	VBN	O
across	IN	O
the	DT	O
mucosa	NN	O
.	.	O
Compositions	NNS	O
suitable	JJ	O
for	IN	O
administration	NN	O
to	TO	O
the	DT	O
respiratory	NN	O
tract	NN	O
include	VBP	O
aerosols	NNS	O
,	,	O
nebulisable	JJ	O
solutions	NNS	O
or	CC	O
micro-fine	JJ	O
powders	NNS	O
for	IN	O
insufflation	NN	O
.	.	O
In	IN	O
the	DT	O
latter	JJ	O
case	NN	O
,	,	O
particle	NN	O
size	NN	O
of	IN	O
less	JJR	O
than	IN	O
50	CD	O
microns	NNS	O
,	,	O
especially	RB	O
less	JJR	O
than	IN	O
10	CD	O
microns	NNS	O
,	,	O
is	VBZ	O
preferred	VBN	O
.	.	O
Compositions	NNS	O
suitable	JJ	O
for	IN	O
topical	JJ	O
mucosal	NN	O
application	NN	O
include	VBP	O
normal	JJ	O
saline	JJ	O
solutions	NNS	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
injections	NNS	O
.	.	O
Other	JJ	O
suitable	JJ	O
compositions	NNS	O
include	VBP	O
gels	NNS	O
and	CC	O
creams	NNS	O
.	.	O
The	DT	O
skin	NN	O
presents	VBZ	O
a	DT	O
formidable	JJ	O
barrier	NN	O
to	TO	O
the	DT	O
application	NN	O
of	IN	O
CnT	NNP	O
.	.	O
CnT	NNP	O
may	MD	O
be	VB	O
mechanically	RB	O
propelled	VBN	O
across	IN	O
the	DT	O
dermal	JJ	O
barrier	NN	O
with	IN	O
air	NN	O
or	CC	O
water	NN	O
pressure	NN	O
injectors	NNS	O
or	CC	O
in	IN	O
association	NN	O
with	IN	O
micro-pellets	NNS	O
.	.	O
Other	JJ	O
suitable	JJ	O
forms	NNS	O
of	IN	O
transdermal	JJ	O
delivery	NN	O
include	VBP	O
iontophoresis	NN	O
.	.	O
CnT	NNP	O
may	MD	O
be	VB	O
encapsulated	VBN	O
into	IN	O
liposomes	NNS	O
or	CC	O
niosomes	NNS	O
to	TO	O
form	VB	O
suitable	JJ	O
trans-dermal	JJ	O
compositions	NNS	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
administration	NN	O
may	MD	O
take	VB	O
many	JJ	O
forms	NNS	O
,	,	O
including	VBG	O
topical	JJ	O
,	,	O
intra-dermal	JJ	O
,	,	O
sub-cutaneous	JJ	O
,	,	O
trans-cutaneous	JJ	O
,	,	O
intra	JJ	O
cavital	NN	O
and	CC	O
by	IN	O
inhalation	NN	O
of	IN	O
the	DT	O
CnT	NNP	O
in	IN	O
a	DT	O
suitable	JJ	O
carrier	NN	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
administration	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
contact	VB	O
with	IN	O
absorbent	JJ	O
pledgets	NNS	O
having	VBG	O
CnT	NNP	O
absorbed	VBD	O
thereon	NN	O
,	,	O
contact	NN	O
with	IN	O
biodegradable	JJ	O
micropellets	NNS	O
having	VBG	O
CnT	NNP	O
embedded	VBD	O
therein	NN	O
.	.	O
Also	RB	O
included	VBN	O
is	VBZ	O
injection	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
injection	NN	O
to	TO	O
the	DT	O
nasal	JJ	O
mucosa	NN	O
or	CC	O
injection	NN	O
into	IN	O
the	DT	O
pterygoplatine	NN	O
space	NN	O
through	IN	O
the	DT	O
palate	NN	O
,	,	O
or	CC	O
injection	NN	O
into	IN	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
surface	NN	O
skin	NN	O
,	,	O
more	RBR	O
invasively	RB	O
,	,	O
by	IN	O
myringotomy	NN	O
and	CC	O
injection	NN	O
into	IN	O
the	DT	O
middle	JJ	O
ear	JJ	O
space	NN	O
across	IN	O
the	DT	O
tympanic	JJ	O
membranes	NNS	O
.	.	O
Alternatively	RB	O
less	RBR	O
invasive	JJ	O
methods	NNS	O
include	VBP	O
by	IN	O
drops	NNS	O
into	IN	O
the	DT	O
inner	JJ	O
eyelid	JJ	O
and	CC	O
inhalation	NN	O
of	IN	O
an	DT	O
aqueous	JJ	O
mist	NN	O
containing	VBG	O
same	JJ	O
.	.	O
The	DT	O
physiological	JJ	O
reaction	NN	O
reactions	NNS	O
dealt	VBP	O
with	IN	O
herein	JJ	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
conditions	NNS	O
such	JJ	O
as	IN	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
infectious	JJ	O
rhinitis	NN	O
,	,	O
vasomotor	NN	O
rhinitis	NN	O
,	,	O
serous	JJ	O
otitis	NN	O
media	NNS	O
,	,	O
sinusitis	NN	O
,	,	O
asthma	NN	O
,	,	O
food	NN	O
allergies	NNS	O
and	CC	O
allergic	JJ	O
dermatitis	NN	O
.	.	O
The	DT	O
amount	NN	O
of	IN	O
CnT	NNP	O
administered	VBD	O
per	IN	O
administration	NN	O
may	MD	O
be	VB	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
between	IN	O
about	RB	O
0.1	CD	O
and	CC	O
about	IN	O
1000	CD	O
units	NNS	O
,	,	O
suitably	RB	O
between	IN	O
about	IN	O
1	CD	O
and	CC	O
about	IN	O
100	CD	O
units	NNS	O
per	IN	O
administration	NN	O
,	,	O
preferably	RB	O
between	IN	O
about	IN	O
1	CD	O
and	CC	O
about	IN	O
20	CD	O
units	NNS	O
.	.	O
The	DT	O
invention	NN	O
is	VBZ	O
also	RB	O
directed	VBN	O
to	TO	O
use	VB	O
of	IN	O
a	DT	O
neurotoxin	NN	O
(	(	O
CnT	NNP	O
)	)	O
derived	VBD	O
from	IN	O
Clostridia	NNP	O
sp	NN	O
.	.	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
blocking	VBG	O
or	CC	O
reducing	VBG	O
physiological	JJ	O
reaction	NN	O
in	IN	O
a	DT	O
mammal	NN	O
to	TO	O
the	DT	O
interaction	NN	O
of	IN	O
IgE	NNP	O
antibodies	NNS	O
present	VBP	O
in	IN	O
said	VBD	O
mammal	JJ	O
upon	IN	O
contact	NN	O
with	IN	O
the	DT	O
corresponding	JJ	O
antigen	NN	O
.	.	O
The	DT	O
formulations	NNS	O
of	IN	O
CnT	NNP	O
,	,	O
including	VBG	O
BoNT	NNP	O
and	CC	O
TeNT	NNP	O
,	,	O
which	WDT	O
are	VBP	O
suitable	JJ	O
for	IN	O
the	DT	O
purposes	NNS	O
designated	VBN	O
herein	NN	O
are	VBP	O
well	RB	O
known	VBN	O
,	,	O
but	CC	O
have	VBP	O
not	RB	O
previously	RB	O
been	VBN	O
designated	VBN	O
for	IN	O
this	DT	O
purpose	NN	O
.	.	O
There	EX	O
is	VBZ	O
a	DT	O
great	JJ	O
need	NN	O
for	IN	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
allergic	JJ	O
disorders	NNS	O
.	.	O
It	PRP	O
has	VBZ	O
long	RB	O
been	VBN	O
thought	VBN	O
that	IN	O
the	DT	O
allergic	JJ	O
reaction	NN	O
involved	VBN	O
only	RB	O
histamine	JJ	O
release	NN	O
by	IN	O
mast	NN	O
cells	NNS	O
.	.	O
Therefore	RB	O
first	JJ	O
line	NN	O
therapy	NN	O
for	IN	O
allergy	NN	O
was	VBD	O
antihistamines	NNS	O
,	,	O
or	CC	O
more	RBR	O
recently	RB	O
the	DT	O
non-sedating	JJ	O
antihistamines	NNS	O
.	.	O
Other	JJ	O
therapies	NNS	O
are	VBP	O
directed	VBN	O
to	TO	O
block	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
mast	NN	O
cell	NN	O
secretions	NNS	O
with	IN	O
adrenergic	JJ	O
agonists	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
not	RB	O
obvious	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
allergic	JJ	O
disorders	NNS	O
involves	VBZ	O
the	DT	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
and	CC	O
that	IN	O
this	DT	O
nerve	NN	O
activity	NN	O
can	MD	O
be	VB	O
blocked	VBN	O
by	IN	O
CnT	NNP	O
for	IN	O
a	DT	O
beneficial	JJ	O
effect	NN	O
.	.	O
It	PRP	O
is	VBZ	O
an	DT	O
object	NN	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
provide	VB	O
a	DT	O
treatment	NN	O
for	IN	O
allergic	JJ	O
conditions	NNS	O
.	.	O
Included	VBN	O
particularly	RB	O
are	VBP	O
allergy	RB	O
related	JJ	O
rhinitis	NN	O
,	,	O
asthma	NN	O
,	,	O
gastroenterititis	NN	O
,	,	O
serous	JJ	O
otitis	NN	O
,	,	O
sinusitis	NN	O
and	CC	O
dermatitis	NN	O
and	CC	O
their	PRP$	O
related	JJ	O
conditions	NNS	O
(	(	O
such	JJ	O
as	IN	O
sinusitis	NN	O
and	CC	O
serous	JJ	O
otitis	NN	O
media	NNS	O
that	WDT	O
occur	VBP	O
secondary	JJ	O
to	TO	O
allergy	VB	O
induced	JJ	O
mucosal	NN	O
swelling	VBG	O
)	)	O
.	.	O
Treatment	NN	O
is	VBZ	O
by	IN	O
local	JJ	O
application	NN	O
of	IN	O
therapeutically	RB	O
effective	JJ	O
amounts	NNS	O
of	IN	O
CnTs	NNP	O
to	TO	O
the	DT	O
body	NN	O
structure	NN	O
and/or	VBZ	O
the	DT	O
nerves	NNS	O
and	CC	O
nerve	NN	O
ganglia	NNS	O
supplying	VBG	O
these	DT	O
structures	NNS	O
.	.	O
CnT	NNP	O
interfere	RB	O
with	IN	O
the	DT	O
allergic	JJ	O
process	NN	O
by	IN	O
:	:	O
1	CD	O
)	)	O
Directly	RB	O
blocking	VBG	O
neuroimmune	JJ	O
secretions	NNS	O
by	IN	O
the	DT	O
mast	NN	O
cell	NN	O
or	CC	O
other	JJ	O
immune	JJ	O
cell	NN	O
types	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
eosinophils	VB	O
2	CD	O
)	)	O
Block	NNP	O
the	DT	O
release	NN	O
of	IN	O
neurohumors	NNS	O
by	IN	O
mast	NN	O
cells	NNS	O
induced	VBN	O
by	IN	O
autonomic	JJ	O
nerve	NN	O
activity	NN	O
.	.	O
3	LS	O
)	)	O
Decrease	NNP	O
neurohumoral	JJ	O
release	NN	O
during	IN	O
axonal	JJ	O
reflexes	NNS	O
.	.	O
4	CD	O
)	)	O
Decrease	NNP	O
the	DT	O
parasympathetic	JJ	O
effector	NN	O
arm	NN	O
of	IN	O
reflex	JJ	O
allergic	JJ	O
responses	NNS	O
5	CD	O
)	)	O
Decrease	NNP	O
the	DT	O
increased	VBN	O
tonic	JJ	O
activity	NN	O
of	IN	O
the	DT	O
autonomic	JJ	O
systemic	NN	O
that	WDT	O
is	VBZ	O
related	VBN	O
to	TO	O
prior	VB	O
allergic	JJ	O
reactions	NNS	O
.	.	O
6	CD	O
)	)	O
Decrease	NNP	O
the	DT	O
enlargement	NN	O
and	CC	O
hypersensitivity	NN	O
of	IN	O
sensory	JJ	O
nerves	NNS	O
induced	VBN	O
by	IN	O
nerve	NN	O
growth	NN	O
factor	NN	O
and	CC	O
other	JJ	O
neurohumors	NNS	O
released	VBN	O
during	IN	O
allergic	JJ	O
reactions	NNS	O
.	.	O
7	CD	O
)	)	O
Reverse	NNP	O
certain	JJ	O
complications	NNS	O
of	IN	O
allergic	JJ	O
reactions	NNS	O
such	JJ	O
as	IN	O
mucosal	NN	O
thickening	NN	O
by	IN	O
decreasing	VBG	O
autonomic	JJ	O
nerve	NN	O
activity	NN	O
.	.	O
The	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
this	DT	O
treatment	NN	O
in	IN	O
the	DT	O
:	:	O
1	CD	O
)	)	O
Nasal	NNP	O
area	NN	O
,	,	O
is	VBZ	O
to	TO	O
decrease	VB	O
the	DT	O
symptoms	NNS	O
of	IN	O
sneezing	NN	O
,	,	O
itching	NN	O
,	,	O
nasal	JJ	O
congestion	NN	O
and	CC	O
post	NN	O
nasal	NN	O
drip	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
related	JJ	O
conditions	NNS	O
including	VBG	O
nasal	JJ	O
polyps	NNS	O
and	CC	O
mucosal	NN	O
thickening	NN	O
,	,	O
and	CC	O
complications	NNS	O
such	JJ	O
as	IN	O
sinusitis	NN	O
and	CC	O
serous	JJ	O
otitis	NN	O
.	.	O
2	CD	O
)	)	O
Lungs	NNS	O
,	,	O
is	VBZ	O
to	TO	O
decrease	VB	O
coughing	NN	O
and	CC	O
wheezing	NN	O
(	(	O
bronchoconstriction	NN	O
,	,	O
edema	NN	O
)	)	O
and	CC	O
the	DT	O
non-specific	JJ	O
sensory	JJ	O
hypersensitivity	NN	O
related	VBN	O
to	TO	O
chronic	JJ	O
allergic	JJ	O
reactions	NNS	O
.	.	O
3	LS	O
)	)	O
Eye	NNP	O
,	,	O
is	VBZ	O
to	TO	O
decrease	VB	O
itching	NN	O
,	,	O
tearing	VBG	O
and	CC	O
redness	NN	O
.	.	O
4	CD	O
)	)	O
Skin	NNP	O
,	,	O
is	VBZ	O
to	TO	O
decrease	VB	O
itching	NN	O
and	CC	O
swelling	NN	O
.	.	O
5	CD	O
)	)	O
Gastrointestinal	NNP	O
tract	NN	O
,	,	O
is	VBZ	O
to	TO	O
decrease	VB	O
gastrointestinal	JJ	O
dysmotility	NN	O
.	.	O
EXAMPLES	NNP	O
Example	NNP	O
1	CD	O
Seasonal	NNP	O
Allergic	NNP	O
Rhinitis	NNP	O
1a	CD	O
)	)	O
A	DT	O
30-year-old	JJ	O
male	NN	O
has	VBZ	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
.	.	O
In	IN	O
May	NNP	O
,	,	O
prior	RB	O
to	TO	O
pollen	VB	O
formation	NN	O
,	,	O
30	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
are	VBP	O
topically	RB	O
applied	VBN	O
in	IN	O
each	DT	O
nostril	NN	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
nasal	JJ	O
cavity	NN	O
is	VBZ	O
sprayed	VBN	O
with	IN	O
a	DT	O
solution	NN	O
of	IN	O
1	CD	O
%	NN	O
lidocaine	NN	O
and	CC	O
½	CD	O
%	NN	O
neosynephrine	NN	O
to	TO	O
anesthetize	VB	O
and	CC	O
decongest	VB	O
the	DT	O
nasal	NN	O
mucosa	NN	O
,	,	O
respectively	RB	O
.	.	O
Then	RB	O
1	CD	O
cc	NNS	O
of	IN	O
normal	JJ	O
saline	NN	O
containing	VBG	O
30	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
sprayed	VBN	O
into	IN	O
each	DT	O
nasal	JJ	O
cavity	NN	O
.	.	O
This	DT	O
method	NN	O
of	IN	O
delivery	NN	O
,	,	O
although	IN	O
commonly	RB	O
used	VBN	O
for	IN	O
application	NN	O
of	IN	O
nasal	JJ	O
medication	NN	O
,	,	O
is	VBZ	O
inherently	RB	O
inefficient	JJ	O
as	IN	O
a	DT	O
significant	JJ	O
percentage	NN	O
of	IN	O
a	DT	O
sprayed	JJ	O
medication	NN	O
will	MD	O
exit	VB	O
the	DT	O
posterior	JJ	O
nasal	JJ	O
cavity	NN	O
and	CC	O
be	VB	O
exhaled	VBN	O
or	CC	O
swallowed	VBN	O
.	.	O
1b	CD	O
)	)	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
treated	VBN	O
by	IN	O
placing	VBG	O
1×3	CD	O
cm2	JJ	O
cotton	NN	O
pledgets	NNS	O
impregnated	VBN	O
with	IN	O
20	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
onto	IN	O
the	DT	O
medial	JJ	O
surface	NN	O
of	IN	O
the	DT	O
turbinates	NNS	O
and	CC	O
left	VBD	O
for	IN	O
one	CD	O
hour	NN	O
,	,	O
then	RB	O
removed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
.	.	O
This	DT	O
delivery	NN	O
method	NN	O
is	VBZ	O
more	RBR	O
efficient	JJ	O
then	RB	O
a	DT	O
spray	NN	O
,	,	O
however	RB	O
a	DT	O
significant	JJ	O
percentage	NN	O
of	IN	O
the	DT	O
BoNT	NNP	O
will	MD	O
not	RB	O
diffuse	VB	O
from	IN	O
the	DT	O
pledgets	NNS	O
to	TO	O
the	DT	O
mucosa	NN	O
.	.	O
1c	CD	O
)	)	O
Alternatively	RB	O
,	,	O
the	DT	O
patient	NN	O
has	VBZ	O
topical	JJ	O
anesthesia	NN	O
applied	VBD	O
only	RB	O
to	TO	O
a	DT	O
localized	JJ	O
area	NN	O
,	,	O
preferably	RB	O
the	DT	O
anterior	JJ	O
end	NN	O
of	IN	O
the	DT	O
inferior	JJ	O
turbinate	NN	O
.	.	O
Then	RB	O
,	,	O
patient	NN	O
has	VBZ	O
a	DT	O
1	CD	O
cm2	JJ	O
cotton	NN	O
pledget	NN	O
impregnated	VBN	O
with	IN	O
10	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
placed	VBD	O
onto	IN	O
the	DT	O
mucosa	NN	O
of	IN	O
the	DT	O
anterior	JJ	O
turbinate	NN	O
for	IN	O
one	CD	O
hour	NN	O
and	CC	O
then	RB	O
removed	VBD	O
.	.	O
Within	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
a	DT	O
mucociliary	JJ	O
blanket	NN	O
transports	NNS	O
fluids	NNS	O
and	CC	O
particles	NNS	O
posteriorly	RB	O
,	,	O
thereby	RB	O
distributing	VBG	O
the	DT	O
BoNT	NNP	O
.	.	O
This	DT	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
applying	VBG	O
a	DT	O
BoNT	NNP	O
to	TO	O
a	DT	O
localized	JJ	O
region	NN	O
of	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
and	CC	O
using	VBG	O
the	DT	O
normal	JJ	O
physiology	NN	O
of	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
for	IN	O
distribution	NN	O
.	.	O
The	DT	O
routes	NNS	O
of	IN	O
mucociliary	JJ	O
clearance	NN	O
of	IN	O
the	DT	O
nose	JJ	O
and	CC	O
sinus	JJ	O
cavities	NNS	O
are	VBP	O
known	VBN	O
so	RB	O
that	IN	O
other	JJ	O
variations	NNS	O
of	IN	O
this	DT	O
method	NN	O
are	VBP	O
apparent	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
1d	CD	O
)	)	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
using	VBG	O
a	DT	O
topical	JJ	O
biodegradable	JJ	O
depot	NN	O
to	TO	O
deliver	VB	O
BoNT	NNP	O
over	IN	O
an	DT	O
extended	JJ	O
time	NN	O
period	NN	O
to	TO	O
nasal	VB	O
mucosa	NN	O
is	VBZ	O
used	VBN	O
for	IN	O
treating	VBG	O
the	DT	O
patient	NN	O
.	.	O
Various	JJ	O
biodegradable	JJ	O
compounds	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
vary	VBP	O
in	IN	O
consistency	NN	O
and	CC	O
rate	NN	O
of	IN	O
dissolution	NN	O
.	.	O
An	DT	O
example	NN	O
is	VBZ	O
oxidized	VBN	O
cellulose	NN	O
(	(	O
marketed	VBN	O
as	IN	O
Surgicel®	NNP	O
by	IN	O
Johnson	NNP	O
&	CC	O
Johnson	NNP	O
,	,	O
New	NNP	O
Brunswick	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
.	.	O
The	DT	O
oxidized	JJ	O
cellulose	NN	O
can	MD	O
be	VB	O
manufactured	VBN	O
with	IN	O
BoNT	NNP	O
as	IN	O
an	DT	O
integral	JJ	O
component	NN	O
,	,	O
or	CC	O
the	DT	O
BoNT	NNP	O
can	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
oxidized	VBN	O
cellulose	NN	O
before	IN	O
its	PRP$	O
clinical	JJ	O
use	NN	O
.	.	O
Surgicel	NNP	O
is	VBZ	O
available	JJ	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
thin	JJ	O
flexible	JJ	O
sheet	NN	O
that	WDT	O
is	VBZ	O
often	RB	O
cut	VBN	O
to	TO	O
fit	VB	O
the	DT	O
area	NN	O
of	IN	O
the	DT	O
body	NN	O
to	TO	O
which	WDT	O
it	PRP	O
will	MD	O
be	VB	O
applied	VBN	O
.	.	O
For	IN	O
intranasal	NN	O
use	VBP	O
the	DT	O
size	NN	O
may	MD	O
vary	VB	O
from	IN	O
a	DT	O
few	JJ	O
square	NN	O
millimeters	NNS	O
to	TO	O
a	DT	O
4	CD	O
by	IN	O
8	CD	O
cm2	JJ	O
sheet	NN	O
that	WDT	O
could	MD	O
contact	VB	O
the	DT	O
entire	JJ	O
exposed	JJ	O
mucosa	NN	O
of	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
.	.	O
BoNT	NNP	O
can	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
Surgicel	NNP	O
as	IN	O
a	DT	O
lyophilized	JJ	O
powder	NN	O
or	CC	O
after	IN	O
reconstitution	NN	O
into	IN	O
solution	NN	O
.	.	O
If	IN	O
added	VBN	O
as	IN	O
a	DT	O
powder	NN	O
it	PRP	O
can	MD	O
homogeneously	RB	O
applied	VBN	O
onto	IN	O
one	CD	O
side	NN	O
of	IN	O
the	DT	O
Surgicel	NNP	O
and	CC	O
the	DT	O
material	NN	O
can	MD	O
be	VB	O
folded	VBN	O
.	.	O
The	DT	O
material	NN	O
is	VBZ	O
then	RB	O
moistened	VBN	O
with	IN	O
normal	JJ	O
saline	NN	O
to	TO	O
bind	VB	O
the	DT	O
material	NN	O
together	RB	O
and	CC	O
immobilize	VB	O
the	DT	O
BoNT	NNP	O
prior	RB	O
to	TO	O
clinical	JJ	O
use	NN	O
.	.	O
In	IN	O
contrast	NN	O
the	DT	O
BoNT	NNP	O
can	MD	O
first	RB	O
be	VB	O
constituted	VBN	O
into	IN	O
solution	NN	O
and	CC	O
then	RB	O
absorbed	VBD	O
into	IN	O
the	DT	O
material	NN	O
.	.	O
As	IN	O
an	DT	O
example	NN	O
a	DT	O
2×6	CD	O
cm2	JJ	O
piece	NN	O
of	IN	O
oxidized	JJ	O
cellulose	NN	O
is	VBZ	O
saturated	VBN	O
with	IN	O
1	CD	O
cc	NNS	O
of	IN	O
normal	JJ	O
saline	NN	O
containing	VBG	O
a	DT	O
total	NN	O
of	IN	O
10	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
.	.	O
Using	VBG	O
a	DT	O
nasal	NN	O
speculum	VBZ	O
the	DT	O
nostril	NN	O
is	VBZ	O
dilated	VBN	O
and	CC	O
the	DT	O
nasal	JJ	O
cavity	NN	O
is	VBZ	O
visualized	VBN	O
and	CC	O
the	DT	O
saturated	VBN	O
cellulose	JJ	O
place	NN	O
therein	NN	O
.	.	O
The	DT	O
cellulose	NN	O
will	MD	O
gradually	RB	O
dissolve	VB	O
over	RP	O
hours	NNS	O
while	IN	O
releasing	VBG	O
a	DT	O
small	JJ	O
continual	JJ	O
dose	NN	O
of	IN	O
BoNT	NNP	O
directly	RB	O
onto	IN	O
the	DT	O
nasal	JJ	O
mucosa	NN	O
.	.	O
Alternatively	RB	O
,	,	O
0.5	CD	O
cc	NN	O
.	.	O
of	IN	O
normal	JJ	O
saline	NN	O
containing	VBG	O
5	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
applied	VBN	O
to	TO	O
the	DT	O
oxidized	VBN	O
cellulose	NN	O
which	WDT	O
is	VBZ	O
grasped	VBN	O
with	IN	O
bayonet	JJ	O
forceps	NNS	O
and	CC	O
placed	VBD	O
flat	JJ	O
onto	IN	O
the	DT	O
medial	JJ	O
surface	NN	O
of	IN	O
the	DT	O
anterior	JJ	O
end	NN	O
of	IN	O
the	DT	O
inferior	JJ	O
turbinate	NN	O
of	IN	O
each	DT	O
nasal	JJ	O
cavity	NN	O
.	.	O
As	IN	O
disclosed	VBN	O
above	IN	O
the	DT	O
mucociliary	JJ	O
action	NN	O
of	IN	O
the	DT	O
nasal	JJ	O
mucosa	NN	O
transports	NNS	O
liquids	NNS	O
and	CC	O
particles	NNS	O
from	IN	O
the	DT	O
anterior	NN	O
to	TO	O
posterior	VB	O
nasal	JJ	O
cavity	NN	O
.	.	O
1e	CD	O
)	)	O
In	IN	O
another	DT	O
embodiment	NN	O
the	DT	O
patient	NN	O
is	VBZ	O
injected	VBN	O
with	IN	O
BoNT	NNP	O
solution	NN	O
directly	RB	O
into	IN	O
the	DT	O
nasal	JJ	O
mucosa	NN	O
.	.	O
After	IN	O
anesthetizing	VBG	O
and	CC	O
decongesting	VBG	O
the	DT	O
mucosa	NN	O
,	,	O
5	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
in	IN	O
1	CD	O
cc	NN	O
of	IN	O
saline	NN	O
are	VBP	O
injected	VBN	O
beneath	IN	O
the	DT	O
mucosa	NN	O
throughout	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
inferior	JJ	O
turbinate	NN	O
with	IN	O
a	DT	O
25	CD	O
gauge	NN	O
spinal	NN	O
needle	NN	O
coupled	VBN	O
to	TO	O
a	DT	O
1	CD	O
cc	NN	O
syringe	NN	O
.	.	O
1f	CD	O
)	)	O
Alternatively	RB	O
the	DT	O
patient	NN	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
TeNT	NNP	O
.	.	O
Compositions	NNS	O
of	IN	O
TeNT	NNP	O
for	IN	O
intranasal	JJ	O
administration	NN	O
,	,	O
can	MD	O
range	VB	O
in	IN	O
dose	NN	O
from	IN	O
0.1	CD	O
to	TO	O
1000	CD	O
units	NNS	O
in	IN	O
0.1	CD	O
cc	NN	O
to	TO	O
10	CD	O
cc	NN	O
of	IN	O
solution	NN	O
.	.	O
One	CD	O
preferable	JJ	O
composition	NN	O
is	VBZ	O
10	CD	O
units	NNS	O
of	IN	O
TeNT	NNP	O
in	IN	O
1	CD	O
cc	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
.	.	O
As	IN	O
an	DT	O
example	NN	O
the	DT	O
same	JJ	O
patient	NN	O
is	VBZ	O
treated	VBN	O
by	IN	O
spraying	VBG	O
each	DT	O
nostril	NN	O
with	IN	O
1	CD	O
cc	NNS	O
of	IN	O
normal	JJ	O
saline	JJ	O
solution	NN	O
containing	VBG	O
10	CD	O
units	NNS	O
of	IN	O
TeNT	NNP	O
.	.	O
Alternatively	RB	O
,	,	O
if	IN	O
only	JJ	O
decongestion	NN	O
is	VBZ	O
desired	VBN	O
10	CD	O
units	NNS	O
of	IN	O
TeNT	NNP	O
can	MD	O
be	VB	O
topically	RB	O
applied	VBN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
1	CD	O
unit	NN	O
of	IN	O
recombinant	JJ	O
DNA	NNP	O
coding	NN	O
for	IN	O
TeNT	NNP	O
is	VBZ	O
pressure	NN	O
injected	VBN	O
across	IN	O
the	DT	O
nasal	NN	O
mucosa	NN	O
to	TO	O
transfect	VB	O
mucosal	NN	O
cells	NNS	O
.	.	O
These	DT	O
cells	NNS	O
then	RB	O
express	VB	O
the	DT	O
TeNT	NNP	O
for	IN	O
months	NNS	O
.	.	O
Example	RB	O
2	CD	O
Perennial	NNP	O
Allergic	NNP	O
Rhinitis	NNP	O
2a	CD	O
)	)	O
Direct	NNP	O
injection	NN	O
of	IN	O
the	DT	O
sphenopalatine	NN	O
ganglia	NN	O
.	.	O
A	DT	O
40-year-old	JJ	O
female	NN	O
has	VBZ	O
chronic	VBN	O
nasal	JJ	O
congestion	NN	O
due	JJ	O
to	TO	O
perennial	JJ	O
rhinitis	NN	O
.	.	O
Skin	NNP	O
testing	VBG	O
demonstrates	NNS	O
that	IN	O
she	PRP	O
is	VBZ	O
allergic	JJ	O
to	TO	O
numerous	JJ	O
environmental	JJ	O
antigens	NNS	O
and	CC	O
intranasal	NN	O
examination	NN	O
shows	NNS	O
enlarged	VBD	O
turbinate	JJ	O
mucosa	NN	O
and	CC	O
nasal	JJ	O
polyps	NNS	O
.	.	O
Testing	VBG	O
of	IN	O
nasal	JJ	O
secretions	NNS	O
shows	VBZ	O
eosinophilia	NNS	O
.	.	O
An	DT	O
injection	NN	O
of	IN	O
20	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
in	IN	O
a	DT	O
1	CD	O
cc	JJ	O
solution	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
is	VBZ	O
made	VBN	O
through	IN	O
the	DT	O
sphenopalatine	JJ	O
canal	NN	O
into	IN	O
the	DT	O
area	NN	O
of	IN	O
the	DT	O
sphenopalatine	NN	O
ganglia	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
100	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
embedded	VBD	O
in	IN	O
0.1	CD	O
micron	NN	O
biodegradable	JJ	O
pellets	NNS	O
suspended	VBN	O
in	IN	O
solution	NN	O
is	VBZ	O
injected	VBN	O
into	IN	O
the	DT	O
mucosa	NN	O
of	IN	O
each	DT	O
turbinate	NN	O
to	TO	O
slowly	VB	O
release	VB	O
its	PRP$	O
contents	NNS	O
over	IN	O
6	CD	O
months	NNS	O
.	.	O
Alternatively	RB	O
a	DT	O
biodegradable	JJ	O
carrier	NN	O
containing	VBG	O
5	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
is	VBZ	O
placed	VBN	O
intranasally	RB	O
in	IN	O
the	DT	O
most	RBS	O
superior	JJ	O
and	CC	O
posterior	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
lateral	JJ	O
nasal	NN	O
wall	NN	O
.	.	O
This	DT	O
permits	VBZ	O
the	DT	O
BoNT	NNP	O
to	TO	O
diffuse	VB	O
across	IN	O
the	DT	O
nasal	NN	O
wall	NN	O
to	TO	O
the	DT	O
underlying	JJ	O
sphenopalatine	NN	O
ganglia	NN	O
.	.	O
Example	RB	O
3	CD	O
Serous	JJ	O
Otitis	NNP	O
Media	NNP	O
A	NNP	O
3-year-old	JJ	O
male	NN	O
has	VBZ	O
a	DT	O
history	NN	O
of	IN	O
serous	JJ	O
otitis	NN	O
media	NNS	O
.	.	O
Under	IN	O
general	JJ	O
anesthesia	NN	O
a	DT	O
myringotomy	NN	O
is	VBZ	O
made	VBN	O
into	IN	O
the	DT	O
tympanic	JJ	O
membranes	NNS	O
and	CC	O
2	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
in	IN	O
0.5	CD	O
cc	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
is	VBZ	O
injected	VBN	O
.	.	O
Example	RB	O
4	CD	O
Sinusitis	VBD	O
A	DT	O
fifty-year-old	JJ	O
male	NN	O
has	VBZ	O
a	DT	O
history	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
and	CC	O
recurrent	NN	O
sinusitis	NN	O
.	.	O
Ten	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
are	VBP	O
injected	VBN	O
through	IN	O
the	DT	O
palate	NN	O
into	IN	O
the	DT	O
pterygopalatine	JJ	O
space	NN	O
to	TO	O
block	VB	O
the	DT	O
sphenopalatine	NN	O
ganglion	NN	O
.	.	O
Example	RB	O
5	CD	O
Allergic	NNP	O
Dermatitis	NNP	O
A	NNP	O
seventy-year-old	JJ	O
male	NN	O
has	VBZ	O
severe	JJ	O
allergic	JJ	O
dermatitis	NN	O
of	IN	O
the	DT	O
forearm	NN	O
skin	NN	O
.	.	O
Each	DT	O
forearm	NN	O
is	VBZ	O
injected	VBN	O
with	IN	O
10	CD	O
injections	NNS	O
of	IN	O
0.3	CD	O
units	NNS	O
BoNT	NNP	O
in	IN	O
0.1	CD	O
cc	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
.	.	O
Each	DT	O
injection	NN	O
is	VBZ	O
made	VBN	O
intradermally	RB	O
at	IN	O
3	CD	O
cm	NN	O
intervals	NNS	O
.	.	O
Example	RB	O
6	CD	O
Allergic	NNP	O
Asthma	NNP	O
A	NNP	O
13-year-old	JJ	O
boy	NN	O
has	VBZ	O
severe	VBN	O
allergic	JJ	O
asthma	NN	O
.	.	O
He	PRP	O
is	VBZ	O
treated	VBN	O
by	IN	O
bimonthly	NN	O
.	.	O
inhalation	NN	O
therapy	NN	O
of	IN	O
an	DT	O
aerosilized	JJ	O
solution	NN	O
of	IN	O
5	CD	O
units	NNS	O
of	IN	O
botulinum	NN	O
toxin	NN	O
in	IN	O
5	CD	O
cc	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
.	.	O
Alternatively	RB	O
the	DT	O
same	JJ	O
botulinum	NN	O
solution	NN	O
can	MD	O
be	VB	O
injected	VBN	O
directly	RB	O
into	IN	O
the	DT	O
trachea	NN	O
and	CC	O
bronchi	NN	O
.	.	O
After	IN	O
injecting	VBG	O
local	JJ	O
anesthesia	NN	O
into	IN	O
the	DT	O
skin	NN	O
overlying	VBG	O
the	DT	O
cricothyroid	NN	O
membrane	NN	O
a	DT	O
needle	NN	O
is	VBZ	O
passed	VBN	O
directly	RB	O
through	IN	O
the	DT	O
skin	NN	O
and	CC	O
cricothyroid	JJ	O
membrane	NN	O
and	CC	O
the	DT	O
BoNT	NNP	O
solution	NN	O
is	VBZ	O
sprayed	VBN	O
into	IN	O
the	DT	O
trachea	NN	O
.	.	O
The	DT	O
solution	NN	O
drips	VBZ	O
down	RB	O
to	TO	O
reach	VB	O
the	DT	O
bronchial	JJ	O
mucosa	NN	O
where	WRB	O
it	PRP	O
is	VBZ	O
topically	RB	O
absorbed	VBN	O
.	.	O
and	CC	O
is	VBZ	O
absorbed	VBN	O
Example	JJ	O
7	CD	O
Allergic	NNP	O
Rhinitis	NNP	O
A	NNP	O
40-year-old	JJ	O
male	NN	O
has	VBZ	O
allergic	VBN	O
rhinitis	NN	O
and	CC	O
an	DT	O
associated	VBN	O
reflex	NN	O
chronic	JJ	O
cough	NN	O
.	.	O
Application	NN	O
of	IN	O
CnT	NNP	O
to	TO	O
the	DT	O
nasal	JJ	O
cavity	NN	O
as	IN	O
described	VBN	O
above	IN	O
or	CC	O
alternatively	RB	O
injected	JJ	O
or	CC	O
aerosilized	JJ	O
topical	JJ	O
application	NN	O
of	IN	O
BoNT	NNP	O
to	TO	O
the	DT	O
lungs	NNS	O
is	VBZ	O
used	VBN	O
to	TO	O
treat	VB	O
the	DT	O
cough	NN	O
.	.	O
Example	RB	O
8	CD	O
Food	NNP	O
Allergies	NNPS	O
A	NNP	O
10-year-old	JJ	O
boy	NN	O
with	IN	O
food	NN	O
allergies	NNS	O
manifested	VBN	O
by	IN	O
bloating	VBG	O
and	CC	O
diarrhea	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
a	DT	O
rectal	JJ	O
suppository	NN	O
containing	VBG	O
50	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
.	.	O
The	DT	O
suppository	NN	O
is	VBZ	O
composed	VBN	O
of	IN	O
biocompatible	JJ	O
material	NN	O
designed	VBN	O
to	TO	O
be	VB	O
solid	JJ	O
at	IN	O
room	NN	O
temperature	NN	O
but	CC	O
to	TO	O
dissolve	VB	O
at	IN	O
body	NN	O
temperature	NN	O
.	.	O
Sufficient	JJ	O
materials	NNS	O
for	IN	O
the	DT	O
composition	NN	O
are	VBP	O
cocoa	JJ	O
butter	NN	O
glycerinated	VBD	O
gelatin	NN	O
,	,	O
hydrogenated	VBD	O
vegetable	JJ	O
oils	NNS	O
,	,	O
polyethylene	NN	O
glycols	NNS	O
of	IN	O
various	JJ	O
molecular	JJ	O
weights	NNS	O
and	CC	O
fatty	JJ	O
esters	NNS	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
.	.	O
Example	RB	O
9	CD	O
Infectious	JJ	O
Rhinitis	NNP	O
Chronic	NNP	O
allergic	NN	O
exposure	NN	O
causes	VBZ	O
the	DT	O
nervous	JJ	O
system	NN	O
to	TO	O
become	VB	O
hyper	JJ	O
responsive	JJ	O
to	TO	O
non-allergic	JJ	O
stimulation	NN	O
such	JJ	O
as	IN	O
that	DT	O
caused	VBN	O
by	IN	O
viral	JJ	O
infections	NNS	O
.	.	O
A	DT	O
patient	NN	O
with	IN	O
rhinitis	NN	O
is	VBZ	O
given	VBN	O
10	CD	O
units	NNS	O
of	IN	O
BoNT	NNP	O
and	CC	O
5	CD	O
units	NNS	O
of	IN	O
TeNT	NNP	O
prior	RB	O
to	TO	O
spring	NN	O
.	.	O
Claims	NNS	O
(	(	O
13	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
2	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
3	CD	O
)	)	O
Related	VBN	O
Child	NNP	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=32393325	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
8	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
1	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
After	IN	O
(	(	O
6	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
6	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
2	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
7	CD	O
)	)	O
Citations	NNPS	O
(	(	O
12	CD	O
)	)	O
Family	RB	O
Cites	VBZ	O
Families	NNS	O
(	(	O
2	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
16	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
20	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
2	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Year	NNP	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
Free	JJ	O
format	NN	O
text	NN	O
:	:	O
ENTITY	NN	O
STATUS	NNP	O
SET	NNP	O
TO	NNP	O
UNDISCOUNTED	NNP	O
(	(	O
ORIGINAL	NNP	O
EVENT	NNP	O
CODE	NNP	O
:	:	O
BIG	NNP	O
.	.	O
)	)	O
